BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21. [PMID: 18536057 DOI: 10.1002/hep.22310] [Cited by in Crossref: 470] [Cited by in F6Publishing: 444] [Article Influence: 36.2] [Reference Citation Analysis]
Number Citing Articles
1 Lederer A, Herrmann P, Seehofer D, Dietel M, Pratschke J, Schlag P, Stein U. Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients. Hepatology. 2015;62:841-850. [PMID: 25953673 DOI: 10.1002/hep.27885] [Cited by in Crossref: 17] [Cited by in F6Publishing: 65] [Article Influence: 2.8] [Reference Citation Analysis]
2 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Luo J, Dong X, Yang F, Zhang M, Zhao J, Wang Q, Zhou F, Sun J, Yang X. Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines. Ann Surg Oncol 2019;26:4134-47. [PMID: 31359275 DOI: 10.1245/s10434-019-07649-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Oldhafer F, Ringe KI, Timrott K, Kleine M, Ramackers W, Cammann S, Jäger MD, Klempnauer J, Bektas H, Vondran FW. Intraoperative Conversion to ALPPS in a Case of Intrahepatic Cholangiocarcinoma. Case Rep Surg 2015;2015:273641. [PMID: 26649219 DOI: 10.1155/2015/273641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Pakharukova MY, Correia da Costa JM, Mordvinov VA, Jamall IS, Brücher BL. The liver fluke Opisthorchis felineus as a group III or group I carcinogen. 4open 2019;2:23. [DOI: 10.1051/fopen/2019016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Qin Y, Cui W, Yang X, Tong B. Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2016;48:238-45. [PMID: 26883800 DOI: 10.1093/abbs/gmv133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
7 Miyata T, Yamashita YI, Baba Y, Harada K, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Shimokawa M, Baba H. Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2018;9:20795-806. [PMID: 29755690 DOI: 10.18632/oncotarget.25124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 2010;24:1718-1730. [PMID: 20675406 DOI: 10.1101/gad.1938710] [Cited by in Crossref: 196] [Cited by in F6Publishing: 190] [Article Influence: 17.8] [Reference Citation Analysis]
9 Zhang XH, Huo L, Liu CF, Xu F, Lu XY, Huang B, Jia NY, Wu L, Shen F. Arterial hyperenhancement of small intrahepatic cholangiocarcinomas correlates with microvessel counts and patient survival. HPB (Oxford) 2020;22:1197-205. [PMID: 31843444 DOI: 10.1016/j.hpb.2019.11.008] [Reference Citation Analysis]
10 Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11:13-21.e1; quiz e3-4. [PMID: 22982100 DOI: 10.1016/j.cgh.2012.09.009] [Cited by in Crossref: 168] [Cited by in F6Publishing: 148] [Article Influence: 18.7] [Reference Citation Analysis]
11 Rahman SU, Sana MK, Tahir Z, Ali A, Shah PA. Paraneoplastic syndromes in cholangiocarcinoma. World J Hepatol 2020; 12(11): 897-907 [PMID: 33312417 DOI: 10.4254/wjh.v12.i11.897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Junking M, Grainok J, Thepmalee C, Wongkham S, Yenchitsomanus PT. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. Tumour Biol. 2017;39:1010428317733367. [PMID: 29034817 DOI: 10.1177/1010428317733367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
13 Cao L, Xue P, Lu H, Zheng Q, Wen Z, Shao Z. Hematoporphyrin derivative-mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivo. Hepatology Research 2009;39:1190-7. [DOI: 10.1111/j.1872-034x.2009.00569.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
14 Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi NJ, Suh KS, Lee KU, Park ES. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010;70:3034-3041. [PMID: 20395200 DOI: 10.1158/0008-5472.can-09-2823] [Cited by in Crossref: 120] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
15 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 11.2] [Reference Citation Analysis]
16 Huang L, Frampton G, Liang LJ, DeMorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol 2010; 1(2): 23-29 [PMID: 21607139 DOI: 10.4291/wjgp.v1.i2.23] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
17 Munoz-Garrido P, Fernandez-Barrena MG, Hijona E, Carracedo M, Marín JJG, Bujanda L, Banales JM. MicroRNAs in biliary diseases. World J Gastroenterol 2012; 18(43): 6189-6196 [PMID: 23180938 DOI: 10.3748/wjg.v18.i43.6189] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
18 Myint KZ, Kongpracha P, Rattanasinganchan P, Leelawat K, Moolthiya P, Chaiyabutr K, Tohtong R. Gadd45β silencing impaired viability and metastatic phenotypes in cholangiocarcinoma cells by modulating the EMT pathway. Oncol Lett 2018;15:3031-41. [PMID: 29435034 DOI: 10.3892/ol.2017.7706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Hirashita T, Iwashita Y, Ohta M, Komori Y, Eguchi H, Yada K, Kitano S. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2012;16:842-848. [PMID: 22246855 DOI: 10.1007/s11605-011-1813-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
20 Taniguchi Y, Kurokawa Y, Hagi T, Takahashi T, Miyazaki Y, Tanaka K, Makino T, Yamasaki M, Nakajima K, Mori M, Doki Y. Methylprednisolone Inhibits Tumor Growth and Peritoneal Seeding Induced by Surgical Stress and Postoperative Complications. Ann Surg Oncol 2019;26:2831-8. [DOI: 10.1245/s10434-019-07585-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wang Y, Ma L, Sheng S, Yuan Z, Zheng J, Li W. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer. Minimally Invasive Therapy & Allied Technologies 2018;27:355-64. [DOI: 10.1080/13645706.2018.1462833] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 2013;34:3637-3648. [PMID: 23832540 DOI: 10.1007/s13277-013-0945-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 8.9] [Reference Citation Analysis]
23 Yang LX, Gao Q, Shi JY, Wang ZC, Zhang Y, Gao PT, Wang XY, Shi YH, Ke AW, Shi GM, Cai JB, Liu WR, Duan M, Zhao YJ, Ji Y, Gao DM, Zhu K, Zhou J, Qiu SJ, Cao Y, Tang QQ, Fan J. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. Hepatology 2015;62:1804-16. [PMID: 26340507 DOI: 10.1002/hep.28149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
24 Vogel A, Wege H, Caca K, Nashan B, Neumann U. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int. 2014;111:748-754. [PMID: 25412632 DOI: 10.3238/arztebl.2014.0748] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
25 Dai M, Yang YW, Guo WH, Wang FL, Xiao GM, Li YM, Yang HZ. Addition and Subtraction Theory of TCM Using Xiao-Chaihu-Decoction and Naturopathy in Predicting Survival Outcomes of Primary Liver Cancer Patients: A Prospective Cohort Study. Evid Based Complement Alternat Med 2016;2016:4723530. [PMID: 27843477 DOI: 10.1155/2016/4723530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Wang W, Zhong W, Yuan J, Yan C, Hu S, Tong Y, Mao Y, Hu T, Zhang B, Song G. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget. 2015;6:42276-42289. [PMID: 26474277 DOI: 10.18632/oncotarget.5514] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
27 Iwasaki A, Kubota K, Kurita Y, Hasegawa S, Fujita Y, Kagawa K, Kato S, Sekino Y, Hosono K, Nakajima A. The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2020;27:700-11. [PMID: 32786134 DOI: 10.1002/jhbp.804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010;51:881-890. [PMID: 20146264 DOI: 10.1002/hep.23381] [Cited by in Crossref: 47] [Cited by in F6Publishing: 171] [Article Influence: 4.3] [Reference Citation Analysis]
29 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-91. [PMID: 19876691 DOI: 10.1245/s10434-009-0777-x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 10.0] [Reference Citation Analysis]
30 Titapun A, Luvira V, Srisuk T, Jareanrat A, Thanasukarn V, Thanee M, Sa-Ngiamwibool P, Padthaisong S, Duangkumpha K, Suksawat M, Loilome W, Sithithaworn P, Techasen A, Thinkhamrop B, Dzienny A, Caglayan A, Park D, Mahmud S, Khuntikeo N. High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection. Int J Gen Med 2021;14:2191-204. [PMID: 34103974 DOI: 10.2147/IJGM.S306339] [Reference Citation Analysis]
31 Dover LL, Jacob R, Wang TN, Richardson JH, Redden DT, Li P, Dubay DA. Improved Postoperative Survival for Intraductal- Growth Subtype of Intrahepatic Cholangiocarcinoma. The American Surgeon 2016;82:1133-9. [DOI: 10.1177/000313481608201132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Arrivé L, Hodoul M, Arbache A, Slavikova-boucher L, Menu Y, El Mouhadi S. Magnetic resonance cholangiography: Current and future perspectives. Clinics and Research in Hepatology and Gastroenterology 2015;39:659-64. [DOI: 10.1016/j.clinre.2015.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
33 Tang C, Yuan P, Wang J, Zhang Y, Chang X, Jin D, Lei P, Lu Z, Chen B. MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway. 3 Biotech 2021;11:99. [PMID: 33552829 DOI: 10.1007/s13205-021-02650-w] [Reference Citation Analysis]
34 Sydor S, Jafoui S, Wingerter L, Swoboda S, Mertens JC, Gerken G, Canbay A, Paul A, Fingas CD. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells. World J Gastroenterol 2017; 23(22): 4007-4015 [PMID: 28652654 DOI: 10.3748/wjg.v23.i22.4007] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chapman R, Williamson K. Primary Sclerosing Cholangitis. The Digestive Involvement in Systemic Autoimmune Diseases. Elsevier; 2017. pp. 119-39. [DOI: 10.1016/b978-0-444-63707-9.00007-6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Nakanuma Y, Xu J, Harada K, Sato Y, Sasaki M, Ikeda H, Kim J, Yu E. Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases. Pathol Int. 2011;61:298-305. [PMID: 21501296 DOI: 10.1111/j.1440-1827.2011.02665.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 72] [Article Influence: 3.2] [Reference Citation Analysis]
37 Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 2011;54:2089-2098. [PMID: 21809359 DOI: 10.1002/hep.24591] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 8.2] [Reference Citation Analysis]
38 Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol 2014;5:E88-95. [PMID: 25436138 DOI: 10.3978/j.issn.2078-6891.2014.051] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
39 Terada M, Horisawa K, Miura S, Takashima Y, Ohkawa Y, Sekiya S, Matsuda-Ito K, Suzuki A. Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma. Sci Rep. 2016;6:34691. [PMID: 27698452 DOI: 10.1038/srep34691] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
40 Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W. Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth. Oncol Lett 2018;16:1627-33. [PMID: 30008846 DOI: 10.3892/ol.2018.8848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009;50:1861-1870. [PMID: 19821497 DOI: 10.1002/hep.23214] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 6.9] [Reference Citation Analysis]
42 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
43 Hormati A, Jafari S, Jabbari A, Pezeshki Modares M, Afifian M, Abasi A, Ahmadpour S, Sharifi AR. Comparison between Brush Cytology and Forceps Biopsy under Fluoroscopic Guidance for the Diagnosis of Proximal Cholangiocarcinoma. Middle East J Dig Dis 2020;12:246-51. [PMID: 33564381 DOI: 10.34172/mejdd.2020.189] [Reference Citation Analysis]
44 Liu J, Qin C. VX-680 induces p53-mediated apoptosis in human cholangiocarcinoma cells. Anti-Cancer Drugs 2018;29:1004-10. [DOI: 10.1097/cad.0000000000000682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bruce-Brand C, Govender D. Gene of the month: IDH1. J Clin Pathol 2020;73:611-5. [PMID: 32727816 DOI: 10.1136/jclinpath-2020-206813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li C, Kang P, Leng K, Ji D, Li Z, Huang L, Qin W, Cui Y. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res 2018;37:81. [PMID: 29642935 DOI: 10.1186/s13046-018-0747-x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 28.3] [Reference Citation Analysis]
47 Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16:117. [PMID: 27655244 DOI: 10.1186/s12876-016-0527-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
48 Jiang F, Ling X. The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development. J Cancer. 2019;10:2407-2414. [PMID: 31258745 DOI: 10.7150/jca.32411] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
49 Kim KB, Choi DW, Heo JS, Han IW, Shin SH, You Y, Park DJ. The impact of portal vein resection on outcome of hilar cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2021;25:221-9. [PMID: 34053925 DOI: 10.14701/ahbps.2021.25.2.221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, Wu L, Wang H, Han SX, Zhu Q. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932-5946. [PMID: 25803229 DOI: 10.18632/oncotarget.3465] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
51 Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010;12:780-786. [PMID: 20864634 DOI: 10.2353/jmoldx.2010.100016] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
52 Mansini AP, Peixoto E, Thelen KM, Gaspari C, Jin S, Gradilone SA. The cholangiocyte primary cilium in health and disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:1245-53. [PMID: 28625917 DOI: 10.1016/j.bbadis.2017.06.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
53 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One 2016;11:e0163699. [PMID: 27685844 DOI: 10.1371/journal.pone.0163699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
55 Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutr Cancer 2016;68:250-66. [PMID: 26943884 DOI: 10.1080/01635581.2016.1145245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
56 Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer 2015;136:844-53. [PMID: 24948044 DOI: 10.1002/ijc.29039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
57 Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G, Chen Y. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget. 2015;6:6310-6325. [PMID: 25749036 DOI: 10.18632/oncotarget.3355] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
58 Wei M, Lü L, Lin P, Chen Z, Quan Z, Tang Z. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma. Cancer Lett 2016;379:253-61. [PMID: 26940139 DOI: 10.1016/j.canlet.2016.02.038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
59 Lee BS, Park EC, Park SW, Nam CM, Roh J. Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in Korea. World J Gastroenterol 2015; 21(2): 502-510 [PMID: 25593465 DOI: 10.3748/wjg.v21.i2.502] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
60 Ikeda C, Haga H, Makino N, Inuzuka T, Kurimoto A, Ueda T, Matsuda A, Kakizaki Y, Ishizawa T, Kobayashi T, Sugahara S, Tsunoda M, Suda K, Ueno Y. Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Sci Rep 2021;11:1195. [PMID: 33441949 DOI: 10.1038/s41598-021-81023-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Wang Y, Wu N, Luo X, Zhang X, Liao Q, Wang J. SOX2OT, a novel tumor-related long non-coding RNA. Biomed Pharmacother 2020;123:109725. [PMID: 31865145 DOI: 10.1016/j.biopha.2019.109725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
62 Fava G. Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol 2010; 1(1): 12-22 [PMID: 21607138 DOI: 10.4291/wjgp.v1.i1.12] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
63 Tomizawa Y, Tian J. Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci. 2012;57:274-283. [PMID: 22057285 DOI: 10.1007/s10620-011-1957-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
64 Schrumpf E, Boberg KM, Karlsen TH. Primary sclerosing cholangitis - the Norwegian experience. Scand J Gastroenterol 2015;50:781-96. [PMID: 25866138 DOI: 10.3109/00365521.2015.1028996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J. Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012;19:2506-2514. [PMID: 22411204 DOI: 10.1245/s10434-012-2268-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
66 Liu W, Tian F, Jiang P, Zhao X, Guo F, Li X, Wang S. Aberrant expression of laminin γ2 correlates with poor prognosis and promotes invasion in extrahepatic cholangiocarcinoma. J Surg Res. 2014;186:150-156. [PMID: 24124977 DOI: 10.1016/j.jss.2013.09.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
67 Li M, Li J, Li P, Li H, Su T, Zhu R, Gong J. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012;27:1561-1568. [PMID: 22694354 DOI: 10.1111/j.1440-1746.2012.07207.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
68 Li Z, Li J, Ji D, Leng K, Xu Y, Huang L, Jiang X, Cui Y. Overexpressed long noncoding RNA Sox2ot predicts poor prognosis for cholangiocarcinoma and promotes cell proliferation and invasion. Gene 2018;645:131-6. [PMID: 29246536 DOI: 10.1016/j.gene.2017.12.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
69 Milkiewicz P, Wunsch E. Primary sclerosing cholangitis. Recent Results Cancer Res. 2011;185:117-133. [PMID: 21822823 DOI: 10.1007/978-3-642-03503-6_7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
70 Plieskatt J, Rinaldi G, Feng Y, Peng J, Easley S, Jia X, Potriquet J, Pairojkul C, Bhudhisawasdi V, Sripa B. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma. BMC Cancer. 2015;15:309. [PMID: 25903557 DOI: 10.1186/s12885-015-1270-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
71 Narahara C, Saeheng T, Chaijaroenkul W, Dumre SP, Na-Bangchang K, Karbwang J. β-Eudesmol induces the expression of apoptosis pathway proteins in cholangiocarcinoma cell lines. J Res Med Sci 2020;25:7. [PMID: 32055247 DOI: 10.4103/jrms.JRMS_291_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, Murphy SJ, McWilliams RR, Hart SN, Halling KC, Roberts LR, Gores GJ, Couch FJ, Zhang L, Borad MJ, Kipp BR. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630-1638. [PMID: 24837095 DOI: 10.1016/j.humpath.2014.03.014] [Cited by in Crossref: 130] [Cited by in F6Publishing: 134] [Article Influence: 18.6] [Reference Citation Analysis]
73 Chua-On D, Proungvitaya T, Tummanatsakun D, Techasen A, Limpaiboon T, Roytrakul S, Wongkham S, Wongkham C, Somintara O, Sangkhamanon S, Proungvitaya S. Apoptosis-Inducing Factor, Mitochondrion-Associated 3 (AIFM3) Protein Level in the Sera as a Prognostic Marker of Cholangiocarcinoma Patients. Biomolecules 2020;10:E1021. [PMID: 32664187 DOI: 10.3390/biom10071021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Lauterio A, De Carlis R, Centonze L, Buscemi V, Incarbone N, Vella I, De Carlis L. Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3657. [PMID: 34359560 DOI: 10.3390/cancers13153657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
76 Kulaksiz H, Strnad P, Römpp A, von Figura G, Barth T, Esposito I, Schirmacher P, Henne-Bruns D, Adler G, Stiehl A. A novel method of forceps biopsy improves the diagnosis of proximal biliary malignancies. Dig Dis Sci 2011;56:596-601. [PMID: 21221795 DOI: 10.1007/s10620-010-1535-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
77 Sasaki M, Nitta T, Sato Y, Nakanuma Y. Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. Hum Pathol. 2015;46:202-209. [PMID: 25466963 DOI: 10.1016/j.humpath.2014.09.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
78 Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc 2016; 8(3): 128-142 [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
79 Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology 2013;58:1362-74. [PMID: 23703673 DOI: 10.1002/hep.26484] [Cited by in Crossref: 28] [Cited by in F6Publishing: 76] [Article Influence: 3.5] [Reference Citation Analysis]
80 Sapisochín G, Fernández de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol 2015; 7(22): 2396-2403 [PMID: 26464755 DOI: 10.4254/wjh.v7.i22.2396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
81 Lee S, Kim JH, Lee JH, Zen Y, Han JK. Imaging Monitoring of Kupffer Cell Function and Hepatic Oxygen Saturation in Preneoplastic Changes During Cholangiocarcinogenesis. Sci Rep 2017;7:14203. [PMID: 29079853 DOI: 10.1038/s41598-017-14218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Cubero FJ, Mohamed MR, Woitok MM, Zhao G, Hatting M, Nevzorova YA, Chen C, Haybaeck J, de Bruin A, Avila MA, Boekschoten MV, Davis RJ, Trautwein C. Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. Hepatol Commun 2020;4:834-51. [PMID: 32490320 DOI: 10.1002/hep4.1495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
83 Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, Hong S, Yu E, Lee M. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid–enhanced MR Imaging and Dynamic CT. Radiology 2017;282:771-81. [DOI: 10.1148/radiol.2016160639] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
84 Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol. 2016;185:61-71. [PMID: 26864161 DOI: 10.1111/cei.12776] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
85 Yin S, Cui Q, Yan K, Yang W, Wu W, Bao L, Chen M. Effect of contrast-enhanced ultrasound on differential diagnosis of intrahepatic cholangiocarcinoma and arterial phase enhanced hepatic inflammatory lesions. Chin J Cancer Res 2017;29:272-80. [PMID: 28729778 DOI: 10.21147/j.issn.1000-9604.2017.03.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
86 Padden J, Ahrens M, Kälsch J, Bertram S, Megger DA, Bracht T, Eisenacher M, Kocabayoglu P, Meyer HE, Sipos B, Baba HA, Sitek B. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells. Mol Cell Proteomics 2016;15:1072-82. [PMID: 26644413 DOI: 10.1074/mcp.M115.054585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
87 Kajioka H, Muraoka A. Rapid recurrence of spindle cell type undifferentiated carcinoma early after radical surgery in a bile duct cancer patient - A case report. Int J Surg Case Rep 2021;81:105800. [PMID: 33756162 DOI: 10.1016/j.ijscr.2021.105800] [Reference Citation Analysis]
88 Vilana R, Forner A, Bianchi L, García-criado Á, Rimola J, Rodríguez de Lope C, Reig M, Ayuso C, Brú C, Bruix J. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-9. [DOI: 10.1002/hep.23600] [Cited by in Crossref: 203] [Cited by in F6Publishing: 176] [Article Influence: 18.5] [Reference Citation Analysis]
89 Kwak TW, Shin HJ, Jeong YI, Han ME, Oh SO, Kim HJ, Kim DH, Kang DH. Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma. Drug Des Devel Ther 2015;9:2201-14. [PMID: 25931814 DOI: 10.2147/DDDT.S80205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
90 Bae YA, Ahn DW, Lee EG, Kim SH, Cai GB, Kang I, Sohn WM, Kong Y. Differential activation of diverse glutathione transferases of Clonorchis sinensis in response to the host bile and oxidative stressors. PLoS Negl Trop Dis 2013;7:e2211. [PMID: 23696907 DOI: 10.1371/journal.pntd.0002211] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
91 Li M, Li K, Qi X, Wu W, Zheng L, He C, Yin Z, Fan D, Zhang Z, Han G. Percutaneous Transhepatic Biliary Stent Implantation for Obstructive Jaundice of Perihilar Cholangiocarcinoma: A Prospective Study on Predictors of Stent Patency and Survival in 92 Patients. Journal of Vascular and Interventional Radiology 2016;27:1047-1055.e2. [DOI: 10.1016/j.jvir.2016.02.035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
92 Seidensticker R, Ricke J, Seidensticker M. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Best Practice & Research Clinical Gastroenterology 2015;29:319-32. [DOI: 10.1016/j.bpg.2015.02.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
93 He F, York JP, Burroughs SG, Qin L, Xia J, Chen D, Quigley EM, Webb P, LeSage GD, Xia X. Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor δ (PPARδ) in human cholangiocarcinoma. Dig Liver Dis 2015;47:62-7. [PMID: 25277864 DOI: 10.1016/j.dld.2014.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
94 Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, Jeong JS, Chun JH. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 2011; 17(35): 4023-4030 [PMID: 22046092 DOI: 10.3748/wjg.v17.i35.4023] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
95 Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-β in Cholangiocarcinoma. Liver Int. 2012;32:400-409. [PMID: 22133064 DOI: 10.1111/j.1478-3231.2011.02687.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
96 Lapumnuaypol K, Tiu A, Thongprayoon C, Wijarnpreecha K, Ungprasert P, Mao MA, Cheungpasitporn W. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. QJM 2019;112:421-7. [PMID: 30753687 DOI: 10.1093/qjmed/hcz039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
97 Wadsworth CA, Lim A, Taylor-robinson SD, Khan SA. The risk factors and diagnosis of cholangiocarcinoma. Hepatol Int 2013;7:377-93. [DOI: 10.1007/s12072-012-9407-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
98 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int. 2011;2011:403929. [PMID: 21559202 DOI: 10.4061/2011/403929] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
99 Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011;54:890-9. [PMID: 21618579 DOI: 10.1002/hep.24466] [Cited by in Crossref: 66] [Cited by in F6Publishing: 112] [Article Influence: 7.3] [Reference Citation Analysis]
100 Garg R, Khan U, AlRajjal A, Kafri Z. Autoimmune Hepatitis: A Risk Factor for Cholangiocarcinoma. Case Rep Gastroenterol 2017;11:672-7. [PMID: 29282390 DOI: 10.1159/000484131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Tsubota A, Matsumoto K, Mogushi K, Nariai K, Namiki Y, Hoshina S, Hano H, Tanaka H, Saito H, Tada N. IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress. Carcinogenesis 2010;31:504-11. [PMID: 20015863 DOI: 10.1093/carcin/bgp313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
102 Poruk KE, Pawlik TM, Weiss MJ. Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg 2015;19:1889-99. [PMID: 26022776 DOI: 10.1007/s11605-015-2854-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
103 Peng NF, Li LQ, Qin X, Guo Y, Peng T, Xiao KY, Chen XG, Yang YF, Su ZX, Chen B, Su M, Qi LN. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol. 2011;18:1258-1266. [PMID: 21207172 DOI: 10.1245/s10434-010-1458-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
104 Duignan S, Maguire D, Ravichand CS, Geoghegan J, Hoti E, Fennelly D, Armstrong J, Rock K, Mohan H, Traynor O. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford). 2014;16:91-98. [PMID: 23600750 DOI: 10.1111/hpb.12082] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
105 Okuno M, Mukai T, Iwata S, Tezuka R, Mita N, Uemura S, Iwashita T, Maruta A, Iwata K, Tomita E, Shimizu M. Preoperative perihilar cholangiocarcinoma assessment using virtual endoscopic imaging magnetic resonance cholangioscopy. Endosc Int Open 2021;9:E1158-63. [PMID: 34222642 DOI: 10.1055/a-1401-9962] [Reference Citation Analysis]
106 Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology. 2009;50:791-798. [PMID: 19610049 DOI: 10.1002/hep.23071] [Cited by in Crossref: 201] [Cited by in F6Publishing: 215] [Article Influence: 16.8] [Reference Citation Analysis]
107 Yonglitthipagon P, Pairojkul C, Bhudhisawasdi V, Mulvenna J, Loukas A, Sripa B. Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma. Clin Biochem 2012;45:827-34. [PMID: 22552009 DOI: 10.1016/j.clinbiochem.2012.04.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
108 Janvilisri T, Leelawat K, Roytrakul S, Paemanee A, Tohtong R. Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach. Dis Markers. 2015;2015:105358. [PMID: 26060332 DOI: 10.1155/2015/105358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
109 Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009;50:1861-1870. [PMID: 19821497 DOI: 10.1002/hep.23214.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16:269-281. [PMID: 30850822 DOI: 10.1038/s41575-019-0125-y] [Cited by in Crossref: 99] [Cited by in F6Publishing: 98] [Article Influence: 49.5] [Reference Citation Analysis]
111 Yothaisong S, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A, Jutabha P, Anzai N, Tassaneeyakul W, Tangsucharit P, Loilome W. Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. Parasitol Int 2017;66:471-8. [PMID: 26657242 DOI: 10.1016/j.parint.2015.11.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
112 Li F, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou J. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol 2020;30:461-70. [DOI: 10.1007/s00330-019-06317-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
113 Wang LJ, Zhang KL, Zhang N, Ma XW, Yan SW, Cao DH, Shi SJ. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget 2015;6:18631-40. [PMID: 26087181 DOI: 10.18632/oncotarget.4072] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
114 Kasemsuk T, Saehlim N, Arsakhant P, Sittithumcharee G, Okada S, Saeeng R. A novel synthetic acanthoic acid analogues and their cytotoxic activity in cholangiocarcinoma cells. Bioorg Med Chem 2021;29:115886. [PMID: 33290909 DOI: 10.1016/j.bmc.2020.115886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Hoffmann K, Luible S, Goeppert B, Weiss K, Hinz U, Büchler MW, Schemmer P. Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma. Surgery 2015;158:1252-60. [DOI: 10.1016/j.surg.2015.04.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
116 Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, Allen PJ, Farges O, Kingham TP, Regimbeau JM, D'Angelica MI, Azoulay D, Jarnagin WR. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg 2016;223:493-505.e2. [PMID: 27296525 DOI: 10.1016/j.jamcollsurg.2016.05.019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
117 Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011;25:753-764. [PMID: 22117640 DOI: 10.1016/j.bpg.2011.10.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
118 Liu T, Zhu G, Yan W, Lv Y, Wang X, Jin G, Cui M, Lin Z, Ren X. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. J Pharmacol Exp Ther 2020;373:279-89. [DOI: 10.1124/jpet.119.263202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
119 Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013;8:e77623. [PMID: 24147037 DOI: 10.1371/journal.pone.0077623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
120 Maeng S, Lee HW, Bashir Q, Kim TI, Hong S, Lee TJ, Sohn W, Na B, Kim T, Pak JH. Oxidative stress-mediated mouse liver lesions caused by Clonorchis sinensis infection. International Journal for Parasitology 2016;46:195-204. [DOI: 10.1016/j.ijpara.2015.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
121 Kato A, Naitoh I, Miyabe K, Hayashi K, Yoshida M, Hori Y, Natsume M, Jinno N, Asano G, Kato H, Kuno T, Takahashi S, Kataoka H. An Increased Chromosome 7 Copy Number in Endoscopic Bile Duct Biopsy Specimens Is Predictive of a Poor Prognosis in Cholangiocarcinoma. Dig Dis Sci 2018;63:3376-81. [PMID: 30206756 DOI: 10.1007/s10620-018-5280-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
122 Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010;4:371-7. [DOI: 10.1007/s11684-010-0130-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
123 Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, Hu J, Wang M, Qin R. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 2013;109:3092-104. [PMID: 24169343 DOI: 10.1038/bjc.2013.655] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
124 Haga H, Yan I, Takahashi K, Wood J, Patel T. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expr 2014;16:93-9. [PMID: 24801170 DOI: 10.3727/105221614X13919976902174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
125 Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer 2017;123:1354-62. [PMID: 27984655 DOI: 10.1002/cncr.30488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
126 Samadder NJ, Smith KR, Wong J, Hanson H, Boucher K, Burt RW, Charlton M, Byrne KR, Gallegos-orozco JF, Koptiuch C, Curtin K. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Dig Dis Sci 2016;61:3627-32. [DOI: 10.1007/s10620-016-4310-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Tsai HM, Chuang CH, Lin XZ, Chen CY. Factors relating to the short term effectiveness of percutaneous biliary drainage for hilar cholangiocarcinoma. World J Gastroenterol 2009; 15(41): 5206-5210 [PMID: 19891021 DOI: 10.3748/wjg.15.5206] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
128 Lee T, Lin J, Kuo KN, Wu M, Ho HJ, Chen T, Wu C. A nationwide population-based study shows increasing incidence of cholangiocarcinoma. Hepatol Int 2013;7:226-32. [DOI: 10.1007/s12072-012-9369-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
129 Gabbert C, Warndorf M, Easler J, Chennat J. Advanced techniques for endoscopic biliary imaging: cholangioscopy, endoscopic ultrasonography, confocal, and beyond. Gastrointest Endosc Clin N Am. 2013;23:625-646. [PMID: 23735107 DOI: 10.1016/j.giec.2013.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
130 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471. [PMID: 21538440 DOI: 10.1002/hep.24397] [Cited by in Crossref: 338] [Cited by in F6Publishing: 357] [Article Influence: 33.8] [Reference Citation Analysis]
131 Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, Soliani P. Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol. 2009;78:133-141. [PMID: 19464430 DOI: 10.1016/j.bcp.2009.04.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
132 Li B, Li B, Guo T, Sun Z, Li X, Li X, Wang H, Chen W, Chen P, Qiao M, Xia L, Mao Y. Application Value of Mass Spectrometry in the Differentiation of Benign and Malignant Liver Tumors. Med Sci Monit 2017;23:1636-44. [PMID: 28376075 DOI: 10.12659/msm.901064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
133 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Davaadorj M, Saito Y, Morine Y, Ikemoto T, Imura S, Takasu C, Yamada S, Hiroki T, Yoshikawa M, Shimada M. Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Eur J Surg Oncol 2017;43:344-50. [PMID: 28062160 DOI: 10.1016/j.ejso.2016.11.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 Liu QD, Chen JZ, Xu XY, Zhang T, Zhou NX. Incidence of port-site metastasis after undergoing robotic surgery for biliary malignancies. World J Gastroenterol 2012; 18(40): 5695-5701 [PMID: 23155309 DOI: 10.3748/wjg.v18.i40.5695] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
136 Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma. Cancer Med 2021;10:5599-613. [PMID: 34245137 DOI: 10.1002/cam4.4121] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Guo Y, Qin X, Chen S, Liu X, Gu P. Diagnosis efficacy of CEUS for hepatic inflammatory lesions. J Clin Lab Anal 2020;34:e23231. [PMID: 32017229 DOI: 10.1002/jcla.23231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Liu J, Xue P, Deng J. Therapeutic effect of photodynamic therapy for nonresectable cholangiocarcinoma: Protocol for a meta-analysis and systematic review. Medicine (Baltimore) 2018;97:e9863. [PMID: 29465572 DOI: 10.1097/MD.0000000000009863] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Allison RR, Zervos E, Sibata CH. Cholangiocarcinoma: An emerging indication for photodynamic therapy. Photodiagnosis and Photodynamic Therapy 2009;6:84-92. [DOI: 10.1016/j.pdpdt.2009.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
140 Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, Lindor KD. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010;51:174-180. [PMID: 19877179 DOI: 10.1002/hep.23277] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 11.5] [Reference Citation Analysis]
141 Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis. 2010;42:390-400. [PMID: 20172772 DOI: 10.1016/j.dld.2010.01.011] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
142 Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579-585. [PMID: 20085587 DOI: 10.1111/j.1349-7006.2009.01458.x] [Cited by in Crossref: 279] [Cited by in F6Publishing: 361] [Article Influence: 23.3] [Reference Citation Analysis]
143 Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion 2014;89:216-24. [PMID: 24860985 DOI: 10.1159/000360791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
144 Wang Y, Wan M, Zhou Q, Wang H, Wang Z, Zhong X, Zhang L, Tai S, Cui Y. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. PLoS One 2015;10:e0141165. [PMID: 26485275 DOI: 10.1371/journal.pone.0141165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
145 Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6:e15640. [PMID: 21253578 DOI: 10.1371/journal.pone.0015640] [Cited by in Crossref: 197] [Cited by in F6Publishing: 200] [Article Influence: 19.7] [Reference Citation Analysis]
146 Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. Cardiovasc Intervent Radiol 2018;41:744-52. [DOI: 10.1007/s00270-017-1871-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
147 Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558. [PMID: 22503487 DOI: 10.1016/j.humpath.2011.12.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 15.2] [Reference Citation Analysis]
148 Zhou H, Wang H, Zhou D, Wang H, Wang Q, Zou S, Tu Q, Wu M, Hu H. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer. 2010;46:1056-1061. [PMID: 20202823 DOI: 10.1016/j.ejca.2010.02.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
149 Wengert GJ, Bickel H, Breitenseher J, Ba-Ssalamah A. [Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma]. Radiologe 2015;55:27-35. [PMID: 25575724 DOI: 10.1007/s00117-014-2705-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Nasr MA, Salah RA, Abd Elkodous M, Elshenawy SE, El-Badri N. Dysregulated MicroRNA Fingerprints and Methylation Patterns in Hepatocellular Carcinoma, Cancer Stem Cells, and Mesenchymal Stem Cells. Front Cell Dev Biol 2019;7:229. [PMID: 31681762 DOI: 10.3389/fcell.2019.00229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
151 Liu GJ, Wang W, Lu MD, Xie XY, Xu HX, Xu ZF, Chen LD, Wang Z, Liang JY, Huang Y, Li W, Liu JY. Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Liver Cancer 2015;4:241-52. [PMID: 26779444 DOI: 10.1159/000367738] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
152 Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci 2017;18:E149. [PMID: 28098760 DOI: 10.3390/ijms18010149] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
153 Yongvanit P, Pinlaor S, Bartsch H. Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. Parasitol Int. 2012;61:130-135. [PMID: 21704729 DOI: 10.1016/j.parint.2011.06.011] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 10.6] [Reference Citation Analysis]
154 Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston M. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:133-8. [PMID: 24046106 DOI: 10.1245/s10434-013-3240-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
155 Qiao P, Li G, Bi W, Yang L, Yao L, Wu D. microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer. 2015;15:469. [PMID: 26077733 DOI: 10.1186/s12885-015-1359-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
156 Guo SS, Wang Y, Fan QX. Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. World J Gastroenterol 2019; 25(26): 3380-3391 [PMID: 31341363 DOI: 10.3748/wjg.v25.i26.3380] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
157 Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantonelli I, Rhönnstad P, Trozzi L, Apelqvist T, Gentile R, Candelaresi C, Fava G, Semeraro R, Benedetti A, Gaudio E, Franchitto A, Onori P, De Minicis S, Carpino G, Kallin E, Alvaro D, Nilsson S. An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Dig Liver Dis 2012;44:134-42. [PMID: 21782536 DOI: 10.1016/j.dld.2011.06.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 75] [Article Influence: 2.7] [Reference Citation Analysis]
158 Zhong X, Yu J, Zhang W, Wang Z, Dong Q, Tai S, Cui Y, Li H. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 2012;493:44-51. [DOI: 10.1016/j.gene.2011.11.028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
159 Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, Margreiter R, Bale R. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2012;35:1074-1082. [PMID: 22006031 DOI: 10.1007/s00270-011-0288-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
160 Tao J, Jiang L, Chen X. Roles of microRNA in liver cancer. Liver Research 2018;2:61-72. [DOI: 10.1016/j.livres.2018.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
161 Esparza-baquer A, Labiano I, Bujanda L, Perugorria MJ, Banales JM. MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. Clinics and Research in Hepatology and Gastroenterology 2016;40:15-27. [DOI: 10.1016/j.clinre.2015.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
162 Sun D, Zhao Y, Wang W, Guan C, Hu Z, Liu L, Jiang X. PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3. Biol Chem 2021;402:207-19. [PMID: 33544468 DOI: 10.1515/hsz-2020-0276] [Reference Citation Analysis]
163 Gi M, Fujioka M, Yamano S, Shimomura E, Ishii N, Kakehashi A, Takeshita M, Wanibuchi H. Determination of Hepatotoxicity and Its Underlying Metabolic Basis of 1,2-Dichloropropane in Male Syrian Hamsters and B6C3F1 Mice. Toxicol Sci 2015;145:196-208. [PMID: 25711234 DOI: 10.1093/toxsci/kfv045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
164 Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010;52:550-61. [PMID: 20683954 DOI: 10.1002/hep.23729] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
165 Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. Journal of Hepatology 2020;73:918-32. [DOI: 10.1016/j.jhep.2020.05.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
166 Navaneethan U, Gutierrez NG, Venkatesh PG, Jegadeesan R, Zhang R, Jang S, Sanaka MR, Vargo JJ, Parsi MA, Feldstein AE. Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study. Am J Gastroenterol. 2014;109:895-902. [PMID: 24710507 DOI: 10.1038/ajg.2014.60] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
167 Wang H, Li C, Jian Z, Ou Y, Ou J. TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLoS One 2015;10:e0136703. [PMID: 26441331 DOI: 10.1371/journal.pone.0136703] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
168 Kitdumrongthum S, Metheetrairut C, Charoensawan V, Ounjai P, Janpipatkul K, Panvongsa W, Weerachayaphorn J, Piyachaturawat P, Chairoungdua A. Dysregulated microRNA expression profiles in cholangiocarcinoma cell-derived exosomes. Life Sci. 2018;210:65-75. [PMID: 30165035 DOI: 10.1016/j.lfs.2018.08.058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
169 Grañé-boladeras N, Pérez-torras S, Lozano JJ, Romero MR, Mazo A, Marín JJ, Pastor-anglada M. Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. Pharmacological Research 2016;113:364-75. [DOI: 10.1016/j.phrs.2016.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
170 Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO). Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831-838. [PMID: 20702152 DOI: 10.1016/j.dld.2010.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
171 Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Chemotherapy. 2012;58:134-141. [PMID: 22572213 DOI: 10.1159/000337289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
172 Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. Experimental and Molecular Pathology 2015;99:344-53. [DOI: 10.1016/j.yexmp.2015.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
173 Wang B, Chen L, Chang HT. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. Biomark Med 2016;10:613-9. [PMID: 27232281 DOI: 10.2217/bmm-2015-0062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
174 An F, Yamanaka S, Allen S, Roberts LR, Gores GJ, Pawlik TM, Xie Q, Ishida M, Mezey E, Ferguson-Smith AC, Mori Y, Selaru FM. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS One. 2012;7:e45606. [PMID: 23110045 DOI: 10.1371/journal.pone.0045606] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
175 Massari NA, Nicoud MB, Medina VA. Histamine receptors and cancer pharmacology: an update. Br J Pharmacol 2020;177:516-38. [PMID: 30414378 DOI: 10.1111/bph.14535] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
176 Chen LD, Ruan SM, Liang JY, Yang Z, Shen SL, Huang Y, Li W, Wang Z, Xie XY, Lu MD, Kuang M, Wang W. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound. World J Gastroenterol 2018; 24(33): 3786-3798 [PMID: 30197484 DOI: 10.3748/wjg.v24.i33.3786] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
177 Cigliano A, Wang J, Chen X, Calvisi DF. Role of the Notch signaling in cholangiocarcinoma. Expert Opin Ther Targets. 2017;21:471-483. [PMID: 28326864 DOI: 10.1080/14728222.2017.1310842] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
178 Beyazit Y, Purnak T, Suvak B, Kurt M, Sayilir A, Turhan T, Tas A, Torun S, Celik T, Ibis M, Haznedaroglu IC. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clinics and Research in Hepatology and Gastroenterology 2011;35:644-9. [DOI: 10.1016/j.clinre.2011.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
179 Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54:2076-2088. [PMID: 22038837 DOI: 10.1002/hep.24588] [Cited by in Crossref: 102] [Cited by in F6Publishing: 144] [Article Influence: 11.3] [Reference Citation Analysis]
180 Keitel V, Reich M, Häussinger D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol 2015;48:218-25. [PMID: 25138774 DOI: 10.1007/s12016-014-8443-x] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
181 Lee J, Hong EM, Jang JA, Park SW, Koh DH, Choi MH, Jang HJ, Kae SH. Simvastatin Induces Apoptosis and Suppresses Insulin-Like Growth Factor 1 Receptor in Bile Duct Cancer Cells. Gut Liver 2016;10:310-7. [PMID: 26470769 DOI: 10.5009/gnl15195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
182 Mendiratta-lala M, Park H, Kolicaj N, Mendiratta V, Bassi D. Small intrahepatic peripheral cholangiocarcinomas as mimics of hepatocellular carcinoma in multiphasic CT. Abdom Radiol 2017;42:171-8. [DOI: 10.1007/s00261-016-0840-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
183 Zou Y, Li R, Kuang D, Zuo M, Li W, Tong W, Jiang L, Zhou M, Chen Y, Gong W, Liu L, Tou F. Galangin Inhibits Cholangiocarcinoma Cell Growth and Metastasis through Downregulation of MicroRNA-21 Expression. Biomed Res Int 2020;2020:5846938. [PMID: 32626749 DOI: 10.1155/2020/5846938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
184 Yang R, Chen Y, Tang C, Li H, Wang B, Yan Q, Hu J, Zou S. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. BMC Cancer 2014;14:917. [PMID: 25479763 DOI: 10.1186/1471-2407-14-917] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
185 Buettner S, Ten Cate DWG, Bagante F, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, Weiss M, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JNM, Pawlik TM, Koerkamp BG. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2019;23:2239-46. [PMID: 30887301 DOI: 10.1007/s11605-019-04184-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
186 Qiu Y, He J, Chen X, Huang P, Hu K, Yan H. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Clin Chim Acta. 2018;480:186-192. [PMID: 29438681 DOI: 10.1016/j.cca.2018.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
187 Lefkowitch JH. Neoplasms and Nodules. Scheuer's Liver Biopsy Interpretation. Elsevier; 2010. pp. 181-231. [DOI: 10.1016/b978-0-7020-3410-7.00017-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
188 Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM, Siveke JT. Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer. Am J Gastroenterol. 2012;107:126-135. [PMID: 21931375 DOI: 10.1038/ajg.2011.305] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
189 Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, Pinlaor S, Yongvanit P, Nielsen PS, Pairojkul C, Khuntikeo N. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumor Biol 2012;33:1785-802. [DOI: 10.1007/s13277-012-0438-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
190 Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979-88. [PMID: 28192597 DOI: 10.1002/cncr.30571] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
191 Marzioni M, Saccomanno S, Candelaresi C, Rychlicki C, Agostinelli L, Trozzi L, De Minicis S, Benedetti A. Clinical implications of novel aspects of biliary pathophysiology. Dig Liver Dis 2010;42:238-44. [PMID: 20167547 DOI: 10.1016/j.dld.2010.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
192 Matsushima H, Kuroki T, Kitasato A, Adachi T, Tanaka T, Hirabaru M, Hirayama T, Kuroshima N, Hidaka M, Soyama A, Takatsuki M, Kinoshita N, Sano K, Nishida N, Eguchi S. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma. Dig Liver Dis. 2015;47:1067-1075. [PMID: 26341967 DOI: 10.1016/j.dld.2015.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
193 Franchitto A, Torrice A, Semeraro R, Napoli C, Nuzzo G, Giuliante F, Alpini G, Carpino G, Berloco PB, Izzo L, Bolognese A, Onori P, Renzi A, Cantafora A, Gaudio E, Alvaro D. Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically. Am J Pathol 2010;177:1779-90. [PMID: 20724592 DOI: 10.2353/ajpath.2010.091171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
194 Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105:131-138. [PMID: 21673683 DOI: 10.1038/bjc.2011.199] [Cited by in Crossref: 73] [Cited by in F6Publishing: 128] [Article Influence: 7.3] [Reference Citation Analysis]
195 Fabris L, Strazzabosco M. Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis 2011;31:11-32. [PMID: 21344348 DOI: 10.1055/s-0031-1272832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
196 Tian F, Li D, Chen J, Liu W, Cai L, Li J, Jiang P, Liu Z, Zhao X, Guo F, Li X, Wang S. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma. Eur J Cancer 2013;49:1771-80. [PMID: 23313142 DOI: 10.1016/j.ejca.2012.12.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
197 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
198 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
199 Lee CH, Wang HE, Seo SY, Kim SH, Kim IH, Kim SW, Lee ST, Kim DG, Han MK, Lee SO. Cancer related gene alterations can be detected with next-generation sequencing analysis of bile in diffusely infiltrating type cholangiocarcinoma. Exp Mol Pathol 2016;101:150-6. [PMID: 27460275 DOI: 10.1016/j.yexmp.2016.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
200 Le Faouder J, Laouirem S, Alexandrov T, Ben-harzallah S, Léger T, Albuquerque M, Bedossa P, Paradis V. Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry: Proteomics 2014. Proteomics 2014;14:965-72. [DOI: 10.1002/pmic.201300463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
201 Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R; AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490-495. [PMID: 20022823 DOI: 10.1016/j.dld.2009.10.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
202 Hu ZQ, Zhou ZJ, Luo CB, Xin HY, Li J, Yu SY, Zhou SL. Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection. Cancer Cell Int 2020;20:582. [PMID: 33292317 DOI: 10.1186/s12935-020-01676-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9:e98612. [PMID: 24874413 DOI: 10.1371/journal.pone.0098612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
204 于泓, 缪林. 胆管癌支架治疗的现状及进展. 世界华人消化杂志 2014; 22(5): 648-653 [DOI: 10.11569/wcjd.v22.i5.648] [Reference Citation Analysis]
205 Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012;122:3914-3918. [PMID: 23023701 DOI: 10.1172/jci63065] [Cited by in Crossref: 201] [Cited by in F6Publishing: 127] [Article Influence: 25.1] [Reference Citation Analysis]
206 Liu H, Ma L, Wang J. Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma. Exp Ther Med 2019;18:2687-94. [PMID: 31555370 DOI: 10.3892/etm.2019.7844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
207 Chung EJ, Jeong YI, Lee MR, Kim YJ, Lee SE, Cho SH, Lee WJ, Park MY, Ju JW. Heat shock proteins 70 and 90 from Clonorchis sinensis induce Th1 response and stimulate antibody production. Parasit Vectors 2017;10:118. [PMID: 28249599 DOI: 10.1186/s13071-017-2026-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
208 Chen Y, Pan Y, Shen KR, Zhu XL, Lu CY, Li QH, Han SG, Fu YB, Xu XF, Yu RS. Contrast-enhanced multiple-phase imaging features of intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma with cirrhosis: A comparative study. Oncol Lett 2017;14:4213-9. [PMID: 28943929 DOI: 10.3892/ol.2017.6656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
209 Bezrookove V, Patino JM, Nosrati M, Desprez PY, McAllister S, Soroceanu L, Baron A, Osorio R, Kashani-Sabet M, Dar AA. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. Cancers (Basel) 2021;13:4405. [PMID: 34503215 DOI: 10.3390/cancers13174405] [Reference Citation Analysis]
210 Kiesslich T, Neureiter D, Wolkersdörfer GW, Plaetzer K, Berr F. Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncol 2010;6:1925-36. [PMID: 21142865 DOI: 10.2217/fon.10.147] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
211 Oliveira DV, Zhang S, Chen X, Calvisi DF, Andersen JB. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Rev Gastroenterol Hepatol. 2017;11:349-356. [PMID: 28162004 DOI: 10.1080/17474124.2017.1292127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
212 Wang B, Yang R, Wu Y, Li H, Hu Z, Chen Y, Zou S. Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo. Gastroenterol Res Pract 2013;2013:374593. [PMID: 24324485 DOI: 10.1155/2013/374593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
213 Farina A, Dumonceau JM, Lescuyer P. Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteomics. 2009;6:285-301. [PMID: 19489700 DOI: 10.1586/epr.09.12] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
214 Su L, Zhang X, Zheng L, Wang M, Zhu Z, Li P. Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism. Front Endocrinol (Lausanne) 2020;11:189. [PMID: 32373065 DOI: 10.3389/fendo.2020.00189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Servajean C, Gilabert M, Piana G, Monges G, Delpero JR, Brenot I, Raoul JL. One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. World J Gastroenterol 2014; 20(17): 5131-5134 [PMID: 24803830 DOI: 10.3748/wjg.v20.i17.5131] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
216 Suzuki A. Artificial induction and disease-related conversion of the hepatic fate. Curr Opin Genet Dev 2013;23:579-84. [PMID: 23702217 DOI: 10.1016/j.gde.2013.04.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
217 Iavarone M, Piscaglia F, Vavassori S, Galassi M, Sangiovanni A, Venerandi L, Forzenigo LV, Golfieri R, Bolondi L, Colombo M. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol. 2013;58:1188-1193. [PMID: 23485522 DOI: 10.1016/j.jhep.2013.02.013] [Cited by in Crossref: 74] [Cited by in F6Publishing: 109] [Article Influence: 9.3] [Reference Citation Analysis]
218 Woradet S, Songserm N, Promthet S, Parkin DM. Health-Related Quality of Life and Survival of Cholangiocarcinoma Patients in Northeastern Region of Thailand. PLoS One 2016;11:e0163448. [PMID: 27685448 DOI: 10.1371/journal.pone.0163448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
219 Crawford JM, Liu C. Liver and Biliary Tract. Robbins and Cotran Pathologic Basis of Disease. Elsevier; 2010. pp. 833-90. [DOI: 10.1016/b978-1-4377-0792-2.50023-7] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
220 Zhang Z, Zang M, Wang S, Wang C. Effects of propofol on human cholangiocarcinoma and the associated mechanisms. Exp Ther Med 2019;17:472-8. [PMID: 30651824 DOI: 10.3892/etm.2018.6908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
221 Chan-On W, Huyen NT, Songtawee N, Suwanjang W, Prachayasittikul S, Prachayasittikul V. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. Drug Des Devel Ther 2015;9:2033-47. [PMID: 25897210 DOI: 10.2147/DDDT.S79313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
222 Ninfole E, Pinto C, Benedetti A, Marzioni M, Maroni L. Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy. World J Clin Cases 2021; 9(22): 6234-6243 [PMID: 34434990 DOI: 10.12998/wjcc.v9.i22.6234] [Reference Citation Analysis]
223 Brito AF, Abrantes AM, Encarnação JC, Tralhão JG, Botelho MF. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 2015;32:245. [PMID: 26427701 DOI: 10.1007/s12032-015-0692-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
224 Pereira SP, Aithal GP, Ragunath K, Devlin J, Owen F, Meadows H. Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. Photodiagnosis Photodyn Ther. 2012;9:287-292. [PMID: 23200007 DOI: 10.1016/j.pdpdt.2012.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
225 Reinhard L, Rupp C, Riedel HD, Ruppert T, Giese T, Flechtenmacher C, Weiss KH, Kloeters-Plachky P, Stremmel W, Schirmacher P. S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One. 2012;7:e29821. [PMID: 22253789 DOI: 10.1371/journal.pone.0029821] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
226 Fevery J, Verslype C. An update on cholangiocarcinoma associated with primary sclerosing cholangitis. Curr Opin Gastroenterol. 2010;26:236-245. [PMID: 20216413 DOI: 10.1097/mog.0b013e328337b311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
227 Bhuria V, Xing J, Scholta T, Bui KC, Nguyen MLT, Malek NP, Bozko P, Plentz RR. Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma. Exp Cell Res 2019;385:111671. [PMID: 31634481 DOI: 10.1016/j.yexcr.2019.111671] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
228 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215-1229. [PMID: 24140396 DOI: 10.1053/j.gastro.2013.10.013] [Cited by in Crossref: 622] [Cited by in F6Publishing: 625] [Article Influence: 77.8] [Reference Citation Analysis]
229 Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-40. [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 34.4] [Reference Citation Analysis]
230 Fraum TJ, Tsai R, Rohe E, Ludwig DR, Salter A, Nalbantoglu I, Heiken JP, Fowler KJ. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology 2018;286:158-72. [PMID: 28853673 DOI: 10.1148/radiol.2017170114] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 17.5] [Reference Citation Analysis]
231 Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology. 2009;50:630-637. [PMID: 19585622 DOI: 10.1002/hep.23010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 6.1] [Reference Citation Analysis]
232 Barr Fritcher EG, Kipp BR, Halling KC, Clayton AC. FISHing for pancreatobiliary tract malignancy in endoscopic brushings enhances the sensitivity of routine cytology. Cytopathology 2014;25:288-301. [PMID: 25073411 DOI: 10.1111/cyt.12170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
233 Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T, Ding Y, Wang W. Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis. Cancer Res Treat 2021;53:184-98. [PMID: 33017884 DOI: 10.4143/crt.2020.192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Reference Citation Analysis]
235 Casper M, Acalovschi M, Lammert F, Zimmer V. The MUTYH hotspot mutations p.G396D and p.Y179C do not cause substantial genetic susceptibility to biliary cancer. Fam Cancer 2014;13:243-7. [PMID: 24420788 DOI: 10.1007/s10689-014-9699-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
236 Wu Z, Boonmars T, Boonjaraspinyo S, Nagano I, Pinlaor S, Puapairoj A, Yongvanit P, Takahashi Y. Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection. Parasitol Res 2011;109:657-73. [DOI: 10.1007/s00436-011-2298-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
237 Enkhbold C, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Ishikawa D, Shimada M. Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Hepatol Res 2014;44:E346-52. [PMID: 24552289 DOI: 10.1111/hepr.12314] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
238 Xiao K, Ouyang Z, Tang HH. Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA. Oncol Lett 2018;16:1841-8. [PMID: 30008874 DOI: 10.3892/ol.2018.8840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
239 Hashimoto K, Miller CM. Liver transplantation for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22:138-143. [PMID: 25214036 DOI: 10.1002/jhbp.159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
240 Cadamuro M, Morton SD, Strazzabosco M, Fabris L. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Transl Gastrointest Cancer. 2013;2:130-144. [PMID: 28989865 DOI: 10.3978/j.issn.2224-4778.2013.04.02] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
241 Juntermanns B, Sydor S, Kaiser GM, Jaradat D, Mertens JC, Sotiropoulos GC, Swoboda S, Neuhaus JP, Meng W, Mathé Z, Baba HA, Canbay A, Paul A, Fingas CD. Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma. Liver Int 2015;35:2448-57. [PMID: 25818805 DOI: 10.1111/liv.12839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
242 Lubezky N, Facciuto M, Harimoto N, Schwartz ME, Florman SS. Surgical treatment of intrahepatic cholangiocarcinoma in the USA. J Hepatobiliary Pancreat Sci. 2015;22:124-130. [PMID: 25187408 DOI: 10.1002/jhbp.157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
243 Choi HJ, Moon JH, Ko BM, Min SK, Song AR, Lee TH, Cheon YK, Cho YD, Park S. Clinical feasibility of direct peroral cholangioscopy–guided photodynamic therapy for inoperable cholangiocarcinoma performed by using an ultra-slim upper endoscope (with videos). Gastrointestinal Endoscopy 2011;73:808-13. [DOI: 10.1016/j.gie.2010.11.049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
244 Samukawa E, Fujihara S, Oura K, Iwama H, Yamana Y, Tadokoro T, Chiyo T, Kobayashi K, Morishita A, Nakahara M, Kobara H, Mori H, Okano K, Suzuki Y, Himoto T, Masaki T. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. Int J Oncol 2017;51:1674-84. [PMID: 29075786 DOI: 10.3892/ijo.2017.4177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
245 Doussot A, Groot-Koerkamp B, Wiggers JK, Chou J, Gonen M, DeMatteo RP, Allen PJ, Kingham TP, D'Angelica MI, Jarnagin WR. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. J Am Coll Surg 2015;221:452-61. [PMID: 26206643 DOI: 10.1016/j.jamcollsurg.2015.04.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
246 Kang P, Wan M, Huang P, Li C, Wang Z, Zhong X, Hu Z, Tai S, Cui Y. The Wnt antagonist sFRP1 as a favorable prognosticator in human biliary tract carcinoma. PLoS One 2014;9:e90308. [PMID: 24594839 DOI: 10.1371/journal.pone.0090308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
247 Buranrat B, Senggunprai L, Prawan A, Kukongviriyapan V. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells. Life Sciences 2016;153:41-9. [DOI: 10.1016/j.lfs.2016.04.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
248 Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, López-andujar R, Palacios F, Ramos E, Fabregat J, Castroagudín JF, Varo E, Pons JA, Parrilla P, González-diéguez ML, Rodriguez M, Otero A, Vazquez MA, Zozaya G, Herrero JI, Antolin GS, Perez B, Ciria R, Rufian S, Fundora Y, Ferron JA, Guiberteau A, Blanco G, Varona MA, Barrera MA, Suarez MA, Santoyo J, Bruix J, Charco R. Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation: A Spanish Matched Cohort Multicenter Study. Annals of Surgery 2014;259:944-52. [DOI: 10.1097/sla.0000000000000494] [Cited by in Crossref: 94] [Cited by in F6Publishing: 35] [Article Influence: 13.4] [Reference Citation Analysis]
249 Ayé Soukhathammavong P, Rajpho V, Phongluxa K, Vonghachack Y, Hattendorf J, Hongvanthong B, Rasaphon O, Sripa B, Akkhavong K, Hatz C, Odermatt P. Subtle to severe hepatobiliary morbidity in Opisthorchis viverrini endemic settings in southern Laos. Acta Trop 2015;141:303-9. [PMID: 25275346 DOI: 10.1016/j.actatropica.2014.09.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
250 Sapisochin G, Rodríguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, Castroagudín JF, Varo E, López-andujar R, Palacios F, Sanchez Antolín G, Perez B, Guiberteau A, Blanco G, González-diéguez ML, Rodriguez M, Varona MA, Barrera MA, Fundora Y, Ferron JA, Ramos E, Fabregat J, Ciria R, Rufian S, Otero A, Vazquez MA, Pons JA, Parrilla P, Zozaya G, Herrero JI, Charco R, Bruix J. “ Very Early ” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?: “ Very Early ” Intrahepatic Cholangiocarcinoma. American Journal of Transplantation 2014;14:660-7. [DOI: 10.1111/ajt.12591] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
251 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-522. [PMID: 21808282 DOI: 10.1038/nrgastro.2011.131] [Cited by in Crossref: 348] [Cited by in F6Publishing: 355] [Article Influence: 34.8] [Reference Citation Analysis]
252 Al-Zahir MZ, AlAmeel T. Extrahepatic cholangiocarcinoma with prolonged survival: a case report. J Med Case Rep 2017;11:357. [PMID: 29275776 DOI: 10.1186/s13256-017-1519-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
253 Wattanavises S, Silsirivanit A, Sawanyawisuth K, Cha'on U, Waraasawapati S, Saentaweesuk W, Luang S, Chalermwat C, Wongkham C, Wongkham S. Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients. Medicina (Kaunas) 2019;55:E761. [PMID: 31795149 DOI: 10.3390/medicina55120761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
254 Lieke T, Ramackers W, Bergmann S, Klempnauer J, Winkler M, Klose J. Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer 2012;12:466. [PMID: 23057720 DOI: 10.1186/1471-2407-12-466] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
255 El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, Wilkens L, Plentz RR. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013;57:1035-45. [DOI: 10.1002/hep.26147] [Cited by in Crossref: 58] [Cited by in F6Publishing: 100] [Article Influence: 7.3] [Reference Citation Analysis]
256 Sasaki M, Nitta T, Sato Y, Nakanuma Y. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. Am J Clin Pathol 2016;145:815-25. [DOI: 10.1093/ajcp/aqw071] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
257 Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019;4:711-20. [PMID: 31300360 DOI: 10.1016/S2468-1253(19)30189-X] [Cited by in Crossref: 69] [Cited by in F6Publishing: 33] [Article Influence: 34.5] [Reference Citation Analysis]
258 Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091-3100. [PMID: 22824796 DOI: 10.1038/onc.2012.315] [Cited by in Crossref: 224] [Cited by in F6Publishing: 275] [Article Influence: 24.9] [Reference Citation Analysis]
259 Takenami T, Maeda S, Karasawa H, Suzuki T, Furukawa T, Morikawa T, Takadate T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Unno M. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer 2019;19:318. [PMID: 30953499 DOI: 10.1186/s12885-019-5548-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
260 Sun C, Zhu J, Wu B, Chen J, Zhu Z, Cai P, Guo W, Gu Z, Wang J, Huang S. Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis. Cancer Manag Res 2018;10:2125-39. [PMID: 30050323 DOI: 10.2147/CMAR.S158155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
261 Romani AA, Desenzani S, Morganti MM, Baroni MC, Borghetti AF, Soliani P. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid. Cancer Chemother Pharmacol. 2011;67:557-567. [PMID: 20473610 DOI: 10.1007/s00280-010-1345-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
262 Song BH, Cha B, Park JS, Jeong S, Lee DH. Effects of microvascular invasion on clinical outcomes after resection with curative intent for cholangiocarcinoma. Medicine (Baltimore) 2020;99:e23668. [PMID: 33350747 DOI: 10.1097/MD.0000000000023668] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Fei F, Qu J, Zhang M, Li Y, Zhang S. S100A4 in cancer progression and metastasis: A systematic review. Oncotarget 2017;8:73219-39. [PMID: 29069865 DOI: 10.18632/oncotarget.18016] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 20.0] [Reference Citation Analysis]
265 Duangkumpha K, Techasen A, Loilome W, Namwat N, Thanan R, Khuntikeo N, Yongvanit P. BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma. Tumour Biol. 2014;35:9667-9676. [PMID: 24969562 DOI: 10.1007/s13277-014-2246-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
266 Kim H, Hwang H, Lee H, Hong HJ. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Mol Cells 2017;40:363-70. [PMID: 28535665 DOI: 10.14348/molcells.2017.2282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
267 Wang M, Xiao J, Shen M, Yahong Y, Tian R, Zhu F, Jiang J, Du Z, Hu J, Liu W. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer. 2011;128:72-81. [PMID: 20232394 DOI: 10.1002/ijc.25317] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
268 Wang B, Li H, Yang R, Zhou S, Zou S. Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts. Oncol Lett 2014;8:1919-24. [PMID: 25295073 DOI: 10.3892/ol.2014.2499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
269 Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U, Buranrat B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One 2012;7:e34994. [PMID: 22514698 DOI: 10.1371/journal.pone.0034994] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
270 Parsi MA. Obesity and cholangiocarcinoma. World J Gastroenterol 2013; 19(4): 457-462 [PMID: 23382624 DOI: 10.3748/wjg.v19.i4.457] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
271 Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer. 2009;100:1765-1770. [PMID: 19436294 DOI: 10.1038/sj.bjc.6605063] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.8] [Reference Citation Analysis]
272 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179. [PMID: 24581682 DOI: 10.1016/s0140-6736(13)61903-0] [Cited by in Crossref: 783] [Cited by in F6Publishing: 476] [Article Influence: 111.9] [Reference Citation Analysis]
273 Sun D, Luo T, Dong P, Zhang N, Chen J, Zhang S, Liu L, Dong L, Zhang S. CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma. PeerJ. 2020;8:e8458. [PMID: 32002338 DOI: 10.7717/peerj.8458] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
274 Berntsen NL, Fosby B, Valestrand L, Tan C, Reims HM, Schrumpf E, Karlsen TH, Line PD, Melum E. Establishment of a surgical bile duct injection technique giving direct access to the bile ducts for studies of the murine biliary tree. Am J Physiol Gastrointest Liver Physiol 2018;314:G349-59. [PMID: 29212771 DOI: 10.1152/ajpgi.00124.2017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
275 Majeed A, Castedal M, Arnelo U, Söderdahl G, Bergquist A, Said K. Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation. Scand J Gastroenterol 2018;53:56-63. [PMID: 28990806 DOI: 10.1080/00365521.2017.1385840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
276 Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T. Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat. 2010;17:742-748. [PMID: 20002305 DOI: 10.1111/j.1365-2893.2009.01243.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
277 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-522. [PMID: 21808282 DOI: 10.1038/nrgastro.2011.131.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
278 Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279-284. [PMID: 19396965 DOI: 10.1097/mog.0b013e328325a894] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
279 Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Tantau M, Cristea V, Irimie A. Molecular markers in the pathogenesis of cholangiocarcinoma: Potential for early detection and selection of appropriate treatment. GR. 2009;2:132-140. [PMID: 27933122 DOI: 10.4021/gr2009.06.1299] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
280 Hariharan D, Constantinides VA, Froeling FE, Tekkis PP, Kocher HM. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers--A meta-analysis. Eur J Surg Oncol. 2010;36:941-948. [PMID: 20547445 DOI: 10.1016/j.ejso.2010.05.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
281 Jiraviriyakul A, Songjang W, Kaewthet P, Tanawatkitichai P, Bayan P, Pongcharoen S. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns. World J Gastroenterol 2019; 25(29): 3941-3955 [PMID: 31413529 DOI: 10.3748/wjg.v25.i29.3941] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
282 Qian Z, Hu W, Lv Z, Liu H, Chen D, Wang Y, Wu J, Zheng S. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol 2020;44:162-73. [PMID: 31303531 DOI: 10.1016/j.clinre.2019.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
283 Boal Carvalho P, Pereira E. Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma. GE Port J Gastroenterol 2015;22:153-60. [PMID: 28868398 DOI: 10.1016/j.jpge.2015.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
284 Hwang IG, Song HS, Lee MA, Nam EM, Lim J, Lee KH, Lee KT, Zang DY, Jang J. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis. Cancer Chemother Pharmacol 2014;74:1291-6. [DOI: 10.1007/s00280-014-2608-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
285 Pant K, Richard S, Peixoto E, Gradilone SA. Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma. Front Med (Lausanne) 2020;7:113. [PMID: 32318579 DOI: 10.3389/fmed.2020.00113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
286 Miller T, Yang F, Wise CE, Meng F, Priester S, Munshi MK, Guerrier M, Dostal DE, Glaser SS. Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Dig Liver Dis 2011;43:395-403. [PMID: 21334995 DOI: 10.1016/j.dld.2011.01.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
287 Fu W, Yu G, Liang J, Fan P, Dong K, Zhang B, Chen X, Zhu H, Chu L. miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4. Front Oncol 2020;10:563486. [PMID: 33520692 DOI: 10.3389/fonc.2020.563486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
288 Untereiner V, Sockalingum GD, Garnotel R, Gobinet C, Ramaholimihaso F, Ehrhard F, Diebold MD, Thiéfin G. Bile analysis using high-throughput FTIR spectroscopy for the diagnosis of malignant biliary strictures: a pilot study in 57 patients. J Biophotonics 2014;7:241-53. [PMID: 24677747 DOI: 10.1002/jbio.201300166] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
289 Saqub H, Proetsch-Gugerbauer H, Bezrookove V, Nosrati M, Vaquero EM, de Semir D, Ice RJ, McAllister S, Soroceanu L, Kashani-Sabet M, Osorio R, Dar AA. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci Rep 2020;10:18489. [PMID: 33116269 DOI: 10.1038/s41598-020-75578-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
290 Zhou X, Wang J, Tang M, Huang M, Xu L, Peng Z, Li ZP, Feng ST. Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge. BMC Cancer. 2020;20:54. [PMID: 31969123 DOI: 10.1186/s12885-020-6539-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
291 Li C, Shen W, Shen S, Ai Z. Gene expression patterns combined with bioinformatics analysis identify genes associated with cholangiocarcinoma. Computational Biology and Chemistry 2013;47:192-7. [DOI: 10.1016/j.compbiolchem.2013.08.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
292 Njei B, McCarty TR, Varadarajulu S, Navaneethan U. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;44:1139-1151. [PMID: 27696456 DOI: 10.1111/apt.13817] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
293 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
294 De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, Alvaro D, Alpini G, Marzioni M. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 2013;45:450-9. [PMID: 23177172 DOI: 10.1016/j.dld.2012.10.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
295 Kozarek RA. Inflammation and carcinogenesis of the biliary tract: update on endoscopic treatment. Clin Gastroenterol Hepatol 2009;7:S89-94. [PMID: 19896106 DOI: 10.1016/j.cgh.2009.08.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
296 Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V. Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 2013;45:612-5. [PMID: 23422030 DOI: 10.1016/j.dld.2012.12.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
297 Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 2015;17:982-7. [PMID: 26607930 DOI: 10.1007/s12094-015-1436-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
298 Liang KH, Yeh TS, Wu RC, Yeh CN, Yeh CT. GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. Oncol Lett 2017;13:4215-23. [PMID: 28588705 DOI: 10.3892/ol.2017.5991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
299 Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 DOI: 10.1186/1470-7330-14-14] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
300 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
301 Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol 2018;9:1063-73. [PMID: 30603125 DOI: 10.21037/jgo.2018.07.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
302 Wang Y, He X, Wei Y, Liu L, Wang W, Li N. SRC-like adaptor protein negatively regulates Wnt signaling in intrahepatic cholangiocarcinoma. Oncol Lett 2019;17:2745-53. [PMID: 30854048 DOI: 10.3892/ol.2019.9901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
303 Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma. Oncotarget 2015;6:18905-20. [PMID: 26056085 DOI: 10.18632/oncotarget.4305] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
304 Sugiyama H, Tsuyuguchi T, Sakai Y, Ohtsuka M, Miyazaki M, Yokosuka O. Potential role of peroral cholangioscopy for preoperative diagnosis of cholangiocarcinoma. Surg Laparosc Endosc Percutan Tech 2012;22:532-6. [PMID: 23238382 DOI: 10.1097/SLE.0b013e3182686178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Chamadol N, Khuntikeo N, Thinkhamrop B, Thinkhamrop K, Suwannatrai AT, Kelly M, Promthet S. Association between periductal fibrosis and bile duct dilatation among a population at high risk of cholangiocarcinoma: a cross-sectional study of cholangiocarcinoma screening in Northeast Thailand. BMJ Open 2019;9:e023217. [PMID: 30898798 DOI: 10.1136/bmjopen-2018-023217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
306 Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595-1601. [PMID: 19296468 DOI: 10.1002/hep.22838] [Cited by in Crossref: 189] [Cited by in F6Publishing: 188] [Article Influence: 15.8] [Reference Citation Analysis]
307 Liu J, Han G, Liu H, Qin C. Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling. PLoS One 2013;8:e62844. [PMID: 23646150 DOI: 10.1371/journal.pone.0062844] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
308 Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer. 2013;119:1669-1674. [PMID: 23335286 DOI: 10.1002/cncr.27955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
309 Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52:297-303. [PMID: 22213236 DOI: 10.1002/mc.21864] [Cited by in Crossref: 225] [Cited by in F6Publishing: 229] [Article Influence: 22.5] [Reference Citation Analysis]
310 Mancinelli R, Onori P, DeMorrow S, Francis H, Glaser S, Franchitto A, Carpino G, Alpini G, Gaudio E. Role of sex hormones in the modulation of cholangiocyte function. World J Gastrointest Pathophysiol 2010; 1(2): 50-62 [PMID: 21607142 DOI: 10.4291/wjgp.v1.i2.50] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
311 Lefkowitch JH. Recent developments in liver pathology. Human Pathology 2009;40:445-55. [DOI: 10.1016/j.humpath.2008.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
312 Hart PA, Law RJ, Dierkhising RA, Smyrk TC, Takahashi N, Chari ST. Risk of cancer in autoimmune pancreatitis: a case-control study and review of the literature. Pancreas. 2014;43:417-421. [PMID: 24622072 DOI: 10.1097/mpa.0000000000000053] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
313 Seeree P, Pearngam P, Kumkate S, Janvilisri T. An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics. 2015;2015:179528. [PMID: 26421274 DOI: 10.1155/2015/179528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
314 Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget 2015;6:23594-608. [PMID: 26090720 DOI: 10.18632/oncotarget.4335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
315 Zhou Y, Wang X, Xu C, Zhou G, Liu X, Gao S, Xu P. Mass‐forming intrahepatic cholangiocarcinoma: Can diffusion‐weighted imaging predict microvascular invasion? J Magn Reson Imaging 2019;50:315-24. [DOI: 10.1002/jmri.26566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
316 Suzuki A. Evidence of cell-fate conversion from hepatocytes to cholangiocytes in the injured liver: in-vivo genetic lineage-tracing approaches. Current Opinion in Gastroenterology 2015;31:247-51. [DOI: 10.1097/mog.0000000000000172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
317 Mihalache F, Hoblinger A, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V. A common variant in the precursor miR-146a sequence does not predispose to cholangiocarcinoma in a large European cohort. Hepatobiliary Pancreat Dis Int 2012;11:412-7. [PMID: 22893469 DOI: 10.1016/s1499-3872(12)60200-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
318 Li S, Qian H, Peng Y, Jia H, Lin G. Differentiating peripheral cholangiocarcinoma in stages T1N0M0 and T2N0M0 from hepatic hypovascular nodules using dynamic contrast-enhanced MRI. Sci Rep 2017;7:8084. [PMID: 28808285 DOI: 10.1038/s41598-017-08634-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
319 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Reference Citation Analysis]
320 Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, Wu CY. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2018; 16: 947-954. e4. [PMID: 28951229 DOI: 10.1016/j.cgh.2017.09.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
321 Nishikawa T, Tsuyuguchi T, Sakai Y, Sugiyama H, Kishimoto T, Ohtsuka M, Miyazaki M, Yokosuka O. Preoperative assessment of longitudinal extension of cholangiocarcinoma with peroral video-cholangioscopy: a prospective study. Dig Endosc 2014;26:450-7. [PMID: 23981193 DOI: 10.1111/den.12159] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
322 Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F, Miyazaki M. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318-324. [PMID: 23149849 DOI: 10.1245/s10434-012-2312-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
323 Pak K, Kim S, Kim IJ, Kim DU, Kim K, Kim H, Kim SJ. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. Nuklearmedizin 2018;53:26-31. [DOI: 10.3413/nukmed-0566-13-03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
324 DeOliveira ML, Kambakamba P, Clavien PA. Advances in liver surgery for cholangiocarcinoma. Curr Opin Gastroenterol. 2013;29:293-298. [PMID: 23563982 DOI: 10.1097/mog.0b013e3283600a92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
325 Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One 2015;10:e0120545. [PMID: 25799509 DOI: 10.1371/journal.pone.0120545] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
326 Kushnir VM, Mullady DK, Das K, Lang G, Hollander TG, Murad FM, Jackson SA, Toney NA, Finkelstein SD, Edmundowicz SA. The Diagnostic Yield of Malignancy Comparing Cytology, FISH, and Molecular Analysis of Cell Free Cytology Brush Supernatant in Patients With Biliary Strictures Undergoing Endoscopic Retrograde Cholangiography (ERC): A Prospective Study. J Clin Gastroenterol 2019;53:686-92. [PMID: 30106834 DOI: 10.1097/MCG.0000000000001118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
327 Farina A, Delhaye M, Lescuyer P, Dumonceau JM. Bile proteome in health and disease. Compr Physiol 2014;4:91-108. [PMID: 24692135 DOI: 10.1002/cphy.c130016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
328 Cheng Q, Feng F, Zhu L, Zheng Y, Luo X, Liu C, Yi B, Jiang X. Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma. Sci Rep. 2015;5:16103. [PMID: 26534789 DOI: 10.1038/srep16103] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
329 Azodo IA, Parks RW, Garden OJ. Epidemiology of Cholangiocarcinoma and Gallbladder Carcinoma. In: Herman JM, Pawlik TM, Thomas, CR, editors. Biliary Tract and Gallbladder Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 1-31. [DOI: 10.1007/978-3-642-40558-7_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
330 Pant K, Peixoto E, Richard S, Gradilone SA. Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma. Cells 2020;9:E780. [PMID: 32210140 DOI: 10.3390/cells9030780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
331 Han J, Liu Y, Han F, Li Q, Yan C, Zheng W, Wang J, Guo Z, Wang J, Li A, Zhou J. The Degree of Contrast Washout on Contrast-Enhanced Ultrasound in Distinguishing Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma. Ultrasound in Medicine & Biology 2015;41:3088-95. [DOI: 10.1016/j.ultrasmedbio.2015.08.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
332 Sasaki M, Nakanuma Y. New concept: cellular senescence in pathophysiology of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2016;10:625-38. [PMID: 26680649 DOI: 10.1586/17474124.2016.1133291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
333 Munoz-garrido P, Marzioni M, Hijona E, Bujanda L, Banales JM. MicroRNAs in Liver Diseases. In: Lawrie CH, editor. MicroRNAs in Medicine. Hoboken: John Wiley & Sons, Inc.; 2013. pp. 509-22. [DOI: 10.1002/9781118300312.ch31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
334 He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, Li X, Li Z, Wang S. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21: Ars2 IS OVEREXPRESSED IN HUMAN CHOLANGIOCARCINOMAS. Mol Carcinog 2013;52:286-96. [DOI: 10.1002/mc.21859] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
335 Shaib WL, Nammour JP, Gill H, Mody M, Saba NF. The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. J Clin Med 2016;5:E100. [PMID: 27854242 DOI: 10.3390/jcm5110100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
336 Mody K, Cleary SP. A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. Front Oncol 2018;8:212. [PMID: 29942792 DOI: 10.3389/fonc.2018.00212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
337 Kalaitzis J, Vezakis A, Fragulidis G, Anagnostopoulou I, Rizos S, Papalambros E, Polydorou A. Effects of endoscopic sphincterotomy on biliary epithelium: A case-control study. World J Gastroenterol 2012; 18(8): 794-799 [PMID: 22371639 DOI: 10.3748/wjg.v18.i8.794] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
338 Hu F, Liu C, Xie F, Lin X, Yang J, Wang C, Huang Q. MSI2 knockdown represses extrahepatic cholangiocarcinoma growth and invasion by inhibiting epithelial-mesenchymal transition. Onco Targets Ther 2018;11:4035-46. [PMID: 30034243 DOI: 10.2147/OTT.S170739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
339 Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 943-950. e3. [PMID: 24360654 DOI: 10.1016/j.gie.2013.11.001] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
340 Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schütte K, Stübs P, Kettner E, Pech M, Amthauer H, Ricke J. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2016;2016:8732521. [PMID: 26966431 DOI: 10.1155/2016/8732521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
341 Zhang J, Han C, Zhu H, Song K, Wu T. miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol 2013;182:1629-39. [PMID: 23608225 DOI: 10.1016/j.ajpath.2013.01.045] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
342 Sibulesky L, Nguyen J, Patel T. Preneoplastic conditions underlying bile duct cancer. Langenbecks Arch Surg 2012;397:861-7. [PMID: 22391777 DOI: 10.1007/s00423-012-0943-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
343 Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology. 2012;143:246-56.e8. [PMID: 22484120 DOI: 10.1053/j.gastro.2012.03.045] [Cited by in Crossref: 117] [Cited by in F6Publishing: 121] [Article Influence: 13.0] [Reference Citation Analysis]
344 郭兴军, 王敏, 江建新, 石程剑, 秦仁义. 姜黄素对胆管癌增殖和凋亡的影响. 世界华人消化杂志 2014; 22(26): 3898-3903 [DOI: 10.11569/wcjd.v22.i26.3898] [Reference Citation Analysis]
345 Huang WC, Tsai CC, Chan CC. Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma. J Formos Med Assoc 2017;116:464-8. [PMID: 27745798 DOI: 10.1016/j.jfma.2016.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
346 Kim TS, Pak JH, Kim JB, Bahk YY. Clonorchis sinensis, an oriental liver fluke, as a human biological agent of cholangiocarcinoma: a brief review. BMB Rep. 2016;49:590-597. [PMID: 27418285 DOI: 10.5483/bmbrep.2016.49.11.109] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
347 Shio S, Kodama Y, Ida H, Shiokawa M, Kitamura K, Hatano E, Uemoto S, Chiba T. Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis. Cancer Science 2011;102:776-83. [DOI: 10.1111/j.1349-7006.2011.01848.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
348 Cheng W, Tian L, Wang B, Qi Y, Huang W, Li H, Chen YJ. Downregulation of HP1α suppresses proliferation of cholangiocarcinoma by restoring SFRP1 expression. Oncotarget 2016;7:48107-19. [PMID: 27385214 DOI: 10.18632/oncotarget.10371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
349 Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, Cairo G, Recalcati S. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Sci Rep 2017;7:17667. [PMID: 29247214 DOI: 10.1038/s41598-017-17804-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
350 Dai J, Wang H, Dong Y, Zhang Y, Wang J. Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway. Cancer Invest 2013;31:111-20. [PMID: 23362950 DOI: 10.3109/07357907.2012.762781] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
351 Li Z, Jiang X, Xiao H, Chen S, Zhu W, Lu H, Cao L, Xue P, Li H, Zhang D. Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma. Surg Endosc 2021;35:5655-64. [PMID: 33104917 DOI: 10.1007/s00464-020-08095-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
352 Chatchawal P, Wongwattanakul M, Tippayawat P, Kochan K, Jearanaikoon N, Wood BR, Jearanaikoon P. Detection of Human Cholangiocarcinoma Markers in Serum Using Infrared Spectroscopy. Cancers (Basel) 2021;13:5109. [PMID: 34680259 DOI: 10.3390/cancers13205109] [Reference Citation Analysis]
353 Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014;184:912-923. [PMID: 24480331 DOI: 10.1016/j.ajpath.2013.12.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 165] [Article Influence: 23.7] [Reference Citation Analysis]
354 Fiorentini G, Mambrini A, Sarti D, Cantore M, Mulazzani L, Mattioli GM, Guadagni S. Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma. Hepat Oncol 2017;4:45-53. [PMID: 30191053 DOI: 10.2217/hep-2017-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Kim DH, Im BN, Hwang HS, Na K. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials 2018;183:139-50. [PMID: 30170256 DOI: 10.1016/j.biomaterials.2018.08.052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
356 Jia X, Lu S, Zeng Z, Liu Q, Dong Z, Chen Y, Zhu Z, Hong Z, Zhang T, Du G, Xiang J, Wu D, Bai W, Yang B, Li Y, Huang J, Li H, Safadi R, Lu Y. Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma. Hepatology 2020;71:893-906. [PMID: 31298745 DOI: 10.1002/hep.30852] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
357 Yongvanit P, Pinlaor S, Loilome W. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:309-15. [DOI: 10.1002/jhbp.63] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
358 Li Z, Jiang X, Huang L, Li J, Ji D, Xu Y, Leng K, Cui Y. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. J Cell Mol Med 2019;23:8258-68. [PMID: 31565837 DOI: 10.1111/jcmm.14698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
359 Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18. [PMID: 30882996 DOI: 10.1111/liv.14093] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 67.0] [Reference Citation Analysis]
360 Kirstein MM, Vogel A. Epidemiology and Risk Factors of Cholangiocarcinoma. Visc Med. 2016;32:395-400. [PMID: 28229073 DOI: 10.1159/000453013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 12.6] [Reference Citation Analysis]
361 Okada R, Shimada H, Otsuka Y, Tsuchiya M, Ishii J, Katagiri T, Maeda T, Kubota Y, Nemoto T, Kaneko H. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma. Surg Today 2017;47:1492-9. [PMID: 28508195 DOI: 10.1007/s00595-017-1540-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
362 Wiecek S, Wojtyniak A, Pindur B, Machnikowska-Sokołowska M, Gruszczyńska K, Grzybowska-Chlebowczyk U. Analysis of the Clinical Course of Primary Sclerosing Cholangitis in Paediatric Population-Single Center Study. Medicina (Kaunas) 2021;57:663. [PMID: 34199130 DOI: 10.3390/medicina57070663] [Reference Citation Analysis]
363 Mihalache F, Höblinger A, Grünhage F, Krawczyk M, Gärtner BC, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther. 2011;33:389-394. [PMID: 21138453 DOI: 10.1111/j.1365-2036.2010.04534.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
364 Papaconstantinou I, Karakatsanis A, Gazouli M, Polymeneas G, Voros D. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 2012;24:223-8. [PMID: 22228372 DOI: 10.1097/MEG.0b013e3283505063] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
365 Zu C, Liu S, Cao W, Liu Z, Qiang H, Li Y, Cheng C, Ji L, Li J, Li J. MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression. Oncotarget 2017;8:34698-708. [PMID: 28423728 DOI: 10.18632/oncotarget.16150] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
366 Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg. 2013;100:274-283. [PMID: 23124720 DOI: 10.1002/bjs.8950] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 13.9] [Reference Citation Analysis]
367 Ehlken H, Schramm C. How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed? Viszeralmedizin 2015;31:173-7. [PMID: 26468311 DOI: 10.1159/000431350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
368 Ha SH, Hwang J, Kim DH, Kim M, Choi C, Jeong Y, Chung CW, Kim CH, Kang DH. Sunitinib release from biodegradable films of poly(l-lactide-co-caprolactone). Materials Research Bulletin 2012;47:2735-8. [DOI: 10.1016/j.materresbull.2012.04.125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
369 Chen X, Chen J, Liu X, Guo Z, Sun X, Zhang J. The real-time dynamic monitoring of microRNA function in cholangiocarcinoma. PLoS One 2014;9:e99431. [PMID: 24918778 DOI: 10.1371/journal.pone.0099431] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
370 Yothaisong S, Dokduang H, Anzai N, Hayashi K, Namwat N, Yongvanit P, Sangkhamanon S, Jutabha P, Endou H, Loilome W. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol 2017;39:1010428317694545. [PMID: 28347255 DOI: 10.1177/1010428317694545] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
371 Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res 2016;76:4775-84. [PMID: 27328733 DOI: 10.1158/0008-5472.CAN-16-0188] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
372 Wang M, Fang M, Zhu J, Feng H, Warner E, Yi C, Ji J, Gu X, Gao C. Serum N -glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma. ELECTROPHORESIS 2017;38:2749-56. [DOI: 10.1002/elps.201700084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
373 Artegiani B, van Voorthuijsen L, Lindeboom RGH, Seinstra D, Heo I, Tapia P, López-Iglesias C, Postrach D, Dayton T, Oka R, Hu H, van Boxtel R, van Es JH, Offerhaus J, Peters PJ, van Rheenen J, Vermeulen M, Clevers H. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids. Cell Stem Cell 2019;24:927-943.e6. [PMID: 31130514 DOI: 10.1016/j.stem.2019.04.017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
374 Njei B, McCarty TR, Varadarajulu S, Navaneethan U. Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastrointest Endosc 2017;85:773-781.e10. [PMID: 27590963 DOI: 10.1016/j.gie.2016.08.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
375 Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol. 2009;40:834-842. [PMID: 19200581 DOI: 10.1016/j.humpath.2008.11.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
376 Zhou DX, Wang H, Zhou H, Li S, Qu HX, Kou X, Li J, Wang H, Hu HP. Over-expression of human carcinoma-associated antigen in intrahepatic cholangiocellular carcinoma. Biochem Biophys Res Commun 2011;405:325-32. [PMID: 21237133 DOI: 10.1016/j.bbrc.2011.01.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
377 Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, Farnell MB, Nagorney DM, Truty MJ, Smoot RL. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB (Oxford). 2016;18:886-892. [PMID: 27546172 DOI: 10.1016/j.hpb.2016.07.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
378 Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013;58:1042-1053. [PMID: 23505219 DOI: 10.1002/hep.26384] [Cited by in Crossref: 92] [Cited by in F6Publishing: 134] [Article Influence: 11.5] [Reference Citation Analysis]
379 Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. Oncotarget. 2018;9:16400-16417. [PMID: 29662654 DOI: 10.18632/oncotarget.24711] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
380 Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, Maitra A, Selaru FM. Coordinated effects of microRNA-494 induce G₂/M arrest in human cholangiocarcinoma. Cell Cycle 2012;11:2729-38. [PMID: 22785131 DOI: 10.4161/cc.21105] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
381 Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas) 2019;55:E42. [PMID: 30743998 DOI: 10.3390/medicina55020042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
382 Shariff MI, Khan SA, Westaby D. The palliation of cholangiocarcinoma. Current Opinion in Supportive & Palliative Care 2013;7:168-74. [DOI: 10.1097/spc.0b013e32835f1e2f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
383 Xiong J, Nunes QM, Huang W, Wei A, Ke N, Mai G, Liu X, Hu W. Major hepatectomy in Bismuth types I and II hilar cholangiocarcinoma. J Surg Res. 2015;194:194-201. [PMID: 25454973 DOI: 10.1016/j.jss.2014.10.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
384 Imperatori M, D'Onofrio L, Marrucci E, Pantano F, Zoccoli A, Tonini G. Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives. Hepat Oncol 2016;3:93-9. [PMID: 30191029 DOI: 10.2217/hep.15.43] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
385 Guedj N, Zhan Q, Perigny M, Rautou P, Degos F, Belghiti J, Farges O, Bedossa P, Paradis V. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. Journal of Hepatology 2009;51:93-101. [DOI: 10.1016/j.jhep.2009.03.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
386 Sriraksa R, Zeller C, Dai W, Siddiq A, Walley AJ, Limpaiboon T, Brown R. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila) 2013;6:1348-55. [PMID: 24089088 DOI: 10.1158/1940-6207.CAPR-13-0104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
387 Xu J, Li D, Li X, Liu Z, Li T, Jiang P, He Q, Tian F, Gao Y, Wang D, Wang S. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. Digestive and Liver Disease 2014;46:750-7. [DOI: 10.1016/j.dld.2014.03.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
388 Wolf S, Lorenz J, Mössner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance. World J Gastroenterol 2010; 16(2): 156-166 [PMID: 20066734 DOI: 10.3748/wjg.v16.i2.156] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
389 Dong ZR, Zhang C, Cai JB, Zhang PF, Shi GM, Gao DM, Sun HC, Qiu SJ, Zhou J, Ke AW. Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma. Tumour Biol. 2015;36:2763-2771. [PMID: 25480415 DOI: 10.1007/s13277-014-2900-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
390 Shen S, Wang J, Zheng B, Tao Y, Li M, Wang Y, Ni X, Suo T, Liu H, Liu H, Zhang J. LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma. Mol Ther Nucleic Acids 2020;19:446-57. [PMID: 31902744 DOI: 10.1016/j.omtn.2019.11.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
391 Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298-1323. [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022] [Cited by in Crossref: 244] [Cited by in F6Publishing: 212] [Article Influence: 61.0] [Reference Citation Analysis]
392 Cen W, Li J, Tong C, Zhang W, Zhao Y, Lu B, Yu J. Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2. J Cancer 2021;12:3448-57. [PMID: 33995623 DOI: 10.7150/jca.55627] [Reference Citation Analysis]
393 Chansitthichok S, Chamnan P, Sarkhampee P, Lertsawatvicha N, Voravisutthikul P, Wattanarath P. Survival of Patients with Cholangiocarcinoma Receiving Surgical Treatment in an O. viverrini Endemic Area in Thailand: A Retrospective Cohort Study. Asian Pac J Cancer Prev 2020;21:903-9. [PMID: 32334449 DOI: 10.31557/APJCP.2020.21.4.903] [Reference Citation Analysis]
394 Suphim B, Prawan A, Kukongviriyapan U, Kongpetch S, Buranrat B, Kukongviriyapan V. Redox modulation and human bile duct cancer inhibition by curcumin. Food and Chemical Toxicology 2010;48:2265-72. [DOI: 10.1016/j.fct.2010.05.059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
395 Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, Sohn H, Lee JM, Kwon W, Jang JY. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. [PMID: 34402435 DOI: 10.14701/ahbps.2021.25.3.349] [Reference Citation Analysis]
396 Lin WR, Yeh CT. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. Int J Mol Sci 2020;21:E1491. [PMID: 32098271 DOI: 10.3390/ijms21041491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
397 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
398 Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861-4870. [PMID: 23318457 DOI: 10.1038/onc.2012.617] [Cited by in Crossref: 140] [Cited by in F6Publishing: 136] [Article Influence: 17.5] [Reference Citation Analysis]
399 Liang Z, Liu X, Zhang Q, Wang C, Zhao Y. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis. 2016;48:1227-1232. [PMID: 27476468 DOI: 10.1016/j.dld.2016.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
400 Elfaki DH, Gossard AA, Lindor KD. Cholangiocarcinoma: Expanding the Spectrum of Risk Factors. J Gastrointest Canc 2008;39:114-7. [DOI: 10.1007/s12029-008-9040-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
401 Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi S, Nguyen HH, Shigemizu D, Abe T, Boroevich KA, Nakano K, Sasaki A, Kitada R, Maejima K, Yamamoto Y, Tanaka H, Shibuya T, Shibata T, Ojima H, Shimada K, Hayami S, Shigekawa Y, Aikata H, Ohdan H, Marubashi S, Yamada T, Kubo M, Hirano S, Ishikawa O, Yamamoto M, Yamaue H, Chayama K, Miyano S, Tsunoda T, Nakagawa H. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015;6:6120. [PMID: 25636086 DOI: 10.1038/ncomms7120] [Cited by in Crossref: 122] [Cited by in F6Publishing: 156] [Article Influence: 20.3] [Reference Citation Analysis]
402 Aishima S, Mano Y, Tanaka Y, Kubo Y, Shirabe K, Maehara Y, Oda Y. Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma. Hum Pathol. 2013;44:1031-1037. [PMID: 23260331 DOI: 10.1016/j.humpath.2012.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
403 Zhou F, Xu J, Ding G, Cao L. Overexpressions of CK2β and XIAP are associated with poor prognosis of patients with cholangiocarcinoma. Pathol Oncol Res 2014;20:73-9. [PMID: 23828693 DOI: 10.1007/s12253-013-9660-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
404 Mulvenna J, Yonglitthipagon P, Sripa B, Brindley PJ, Loukas A, Bethony JM. Banking on the future: biobanking for “omics” approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand. Parasitol Int. 2012;61:173-177. [PMID: 21855650 DOI: 10.1016/j.parint.2011.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
405 Raggi C, Invernizzi P. Methylation and liver cancer. Clin Res Hepatol Gastroenterol 2013;37:564-71. [PMID: 23806627 DOI: 10.1016/j.clinre.2013.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
406 Pak JH, Kim IK, Kim SM, Maeng S, Song KJ, Na B, Kim T. Induction of cancer-related microRNA expression profiling using excretory-secretory products of Clonorchis sinensis. Parasitol Res 2014;113:4447-55. [DOI: 10.1007/s00436-014-4127-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
407 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
408 Zhou J, Liu Z, Yang S, Li X. Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:156-162. [PMID: 27939910 DOI: 10.1016/j.clinre.2016.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
409 Zimmer V, Höblinger A, Mihalache F, Assmann G, Acalovschi M, Lammert F. Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility. Oncol Lett 2012;4:101-6. [PMID: 22807971 DOI: 10.3892/ol.2012.680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
410 Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, Heim MH, Tchorz JS. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology. 2013;57:1607-1619. [PMID: 23175466 DOI: 10.1002/hep.26165] [Cited by in Crossref: 87] [Cited by in F6Publishing: 131] [Article Influence: 10.9] [Reference Citation Analysis]
411 Macias RI. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol 2014;2014:828074. [PMID: 27335842 DOI: 10.1155/2014/828074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
412 Lu Q, Xue LY, Wang WP, Huang BJ, Li CX. Dynamic enhancement pattern of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: the correlation with cirrhosis and tumor size. Abdom Imaging. 2015;40:1558-1566. [PMID: 25725793 DOI: 10.1007/s00261-015-0379-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
413 Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C, Namwat N. Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse. Cancers (Basel) 2021;13:2134. [PMID: 33925189 DOI: 10.3390/cancers13092134] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
414 Li R, Zhang X, Ma KS, Li XW, Xia F, Zhong H, Tang CL, Guo Y, Yan XC. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging. 2013;38:112-119. [PMID: 22323003 DOI: 10.1007/s00261-012-9854-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
415 Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, Zheng QC. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4:457-462. [PMID: 21191748 DOI: 10.1007/s11684-010-0240-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
416 Hirata M, Nagai A, Kamatani Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Kiyohara Y, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y, Matsuda K; BioBank Japan Cooperative Hospital Group. Overview of BioBank Japan follow-up data in 32 diseases. J Epidemiol 2017;27:S22-8. [PMID: 28190660 DOI: 10.1016/j.je.2016.12.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
417 Sripa B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, Mulvenna J, Laha T, Hotez PJ, Brindley PJ. Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 2011;120 Suppl 1:S158-S168. [PMID: 20655862 DOI: 10.1016/j.actatropica.2010.07.006] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 17.7] [Reference Citation Analysis]
418 Xu Y, Wang Z, Jiang X, Cui Y. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Biomed Pharmacother 2017;92:17-23. [PMID: 28528181 DOI: 10.1016/j.biopha.2017.05.061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
419 Kaneko S, Kurosaki M, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Itakura J, Takahashi Y, Nakanishi H, Asano D, Irie T, Kawachi Y, Izumi N. Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatol Res 2021;51:902-8. [PMID: 34046984 DOI: 10.1111/hepr.13673] [Reference Citation Analysis]
420 Gao L, Yang X, Zhang H, Yu M, Long J, Yang T. Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway. Onco Targets Ther 2018;11:6981-94. [PMID: 30410355 DOI: 10.2147/OTT.S182225] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
421 Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013;45:1474-8. [PMID: 24185513 DOI: 10.1038/ng.2806] [Cited by in Crossref: 282] [Cited by in F6Publishing: 322] [Article Influence: 35.3] [Reference Citation Analysis]
422 Chen H, Chen S, Huang Z, Kong L, Hu Z, Qin S, Qin X, Li S. Relationship between blood parameters and Clonorchis sinensis infection: A retrospective single center study. Int Immunopharmacol 2018;59:120-6. [PMID: 29653409 DOI: 10.1016/j.intimp.2018.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
423 Graziadei I. [Overview: liver tumors]. Wien Med Wochenschr 2013;163:109-12. [PMID: 23361850 DOI: 10.1007/s10354-013-0177-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
424 Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong Q, Tai S, Li H, Cui YF. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep 2012;27:1266-76. [PMID: 22209942 DOI: 10.3892/or.2011.1617] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
425 Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdörfer GW, Berr F, Hauss J, Witzigmann H. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci 2015;16:26619-28. [PMID: 26561801 DOI: 10.3390/ijms161125978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
426 Keitel V, Häussinger D. TGR5 in cholangiocytes. Curr Opin Gastroenterol 2013;29:299-304. [PMID: 23429467 DOI: 10.1097/MOG.0b013e32835f3f14] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
427 Silsirivanit A, Sawanyawisuth K, Riggins GJ, Wongkham C. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci 2014;21:388-96. [PMID: 24616382 DOI: 10.1002/jhbp.68] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
428 Wang J, Wang X, Xie S, Yan Z, Li Z, Li Y, Wang L, Jiao F. p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies. Dig Dis Sci 2011;56:655-62. [DOI: 10.1007/s10620-010-1352-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
429 Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, Chiorino G, Forti E, Glaser S, Alpini G, Destro A, Sozio F, Di Tommaso L, Roncalli M, Banales JM, Coulouarn C, Bujanda L, Torzilli G, Invernizzi P. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J Hepatol. 2017;66:102-115. [PMID: 27593106 DOI: 10.1016/j.jhep.2016.08.012] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 14.4] [Reference Citation Analysis]
430 Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280 [PMID: 28808500 DOI: 10.4251/wjgo.v9.i7.268] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
431 Zhang GW, Lin JH, Qian JP, Zhou J. Identification of risk and prognostic factors for patients with clonorchiasis-associated intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2014;21:3628-3637. [PMID: 24781504 DOI: 10.1245/s10434-014-3710-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
432 Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol. 2011;46:779-789. [PMID: 21331764 DOI: 10.1007/s00535-011-0380-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
433 Ware MB, Zaidi MY, Yang J, Turgeon MK, Krasinskas A, Mace TA, Keenan K, Farren MR, Ruggieri AN, Li Y, Zhang C, Chen Z, Young GS, Elnaggar O, Che Z, Maithel SK, Bekaii-saab T, El-rayes B, Lesinski GB. Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. Br J Cancer 2020;123:1377-86. [DOI: 10.1038/s41416-020-1018-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
434 Li L, Guo HJ, Zhu LY, Zheng L, Liu X. A supercritical-CO2 extract of Ganoderma lucidum spores inhibits cholangiocarcinoma cell migration by reversing the epithelial-mesenchymal transition. Phytomedicine 2016;23:491-7. [PMID: 27064008 DOI: 10.1016/j.phymed.2016.02.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
435 Recalcati S, Correnti M, Gammella E, Raggi C, Invernizzi P, Cairo G. Iron Metabolism in Liver Cancer Stem Cells. Front Oncol 2019;9:149. [PMID: 30941302 DOI: 10.3389/fonc.2019.00149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
436 Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54:2238-2244. [PMID: 21932394 DOI: 10.1002/hep.24670] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
437 Siripanthong S, Techasen A, Nantasenamat C, Malik AA, Sithithaworn P, Leelayuwat C, Jumnainsong A. Production and characterization of antibody against Opisthorchis viverrini via phage display and molecular simulation. PLoS One 2021;16:e0248887. [PMID: 33755687 DOI: 10.1371/journal.pone.0248887] [Reference Citation Analysis]
438 Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech. 2013;6:281-292. [PMID: 23520144 DOI: 10.1242/dmm.010561] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
439 Carrafiello G, Laganà D, Cotta E, Mangini M, Fontana F, Bandiera F, Fugazzola C. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol. 2010;33:835-839. [PMID: 20411389 DOI: 10.1007/s00270-010-9849-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
440 Kato A, Naitoh I, Miyabe K, Hayashi K, Kondo H, Yoshida M, Kato H, Kuno T, Takahashi S, Joh T. Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence in situ hybridization using transpapillary forceps biopsy specimens. J Hepatobiliary Pancreat Sci 2018;25:188-94. [DOI: 10.1002/jhbp.536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
441 Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol. 2014;44:570-578. [PMID: 24755544 DOI: 10.1093/jjco/hyu045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
442 Folseraas T, Boberg KM. Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. Clin Liver Dis. 2016;20:79-98. [PMID: 26593292 DOI: 10.1016/j.cld.2015.08.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
443 Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouillères O, Arrivé L. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 2014;59:242-50. [PMID: 23857427 DOI: 10.1002/hep.26620] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
444 Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T, Tsung A, Tohme S, Huang H, Zhang Q, Lencioni R, Zeng Z, Peng B, Chen M, Kuang M. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. Cancer Lett. 2016;373:193-202. [PMID: 26805764 DOI: 10.1016/j.canlet.2016.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]